Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
04 July 2026 :: Issue 852

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. Th e PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: Milestones, Perspectives
:: WHO
:: U.S. Immunization and Public Health Governance/Policy/Funding
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
:: Think Tanks
:: Public Consultations/Call for Inputs/Call for Papers

This week's edition is published later than usual reflecting the national holiday in the U.S.

Milestones, Perspectives

::::::::
::::::::

Gavi

Gavi Board meeting underlines commitment to country sovereignty, fragility and health security

:: Board agrees to maintain ambitious targets for Gavi 6.0, including reaching 500 million children, preventing 8–9 million deaths and further reducing under-five mortality by 10%
:: Programmatic decisions underline commitment to country leadership and support for fragile and humanitarian contexts
:: Additional US$ 189 million in support approved for sustainable African vaccine manufacturing, enhancing supply resilience and health security
:: Decisions include innovations that will help Gavi, countries and health workers deliver on 6.0 targets – such as digital payments for vaccination campaigns and flexible liquidity through the European Investment Bank Frontloading Facility

2 July 2026
[Excerpts]

Gavi 6.0 targets finalised

Despite the financially constrained environment within which the Alliance is operating, Gavi's Board agreed to maintain the ambition to reach 500 million more children, prevent an additional 8–9 million deaths, support a further 10% reduction in under-five mortality and unlock more than US$ 100 billion in economic benefits. Achieving these targets will require continued engagement with sovereign and philanthropic donors to close the funding gap for Gavi 6.0.

In the meantime, innovative financing mechanisms that enable flexible liquidity will be key to delivering Gavi 6.0 in an era of volatility. In this spirit, the Board approved the extension of the European Investment Bank (EIB) Frontloading Facility until end 2026, as well as Gavi's ability to draw down up to €500 million from the Facility, backed by donor pledges, to ensure continuity of core Gavi activities…

Renewed focus on country ownership, fragile contexts

A number of measures were also passed that will strengthen country ownership of immunisation programmes. These included new policies on country vaccine budgets and co-financing for preventive vaccination campaigns, both of which have been tailored to provide the highest levels of support for countries and contexts with the greatest need. The approach to campaigns will also prioritise, where feasible, digital payments as the default mechanism for health worker payments to avoid delays, misuse and other risks. In line with the principle to prioritise the needs of the most vulnerable, the Board agreed to use cases for its new approach to support fragile and humanitarian contexts. During 6.0, this will include up to US$ 100 million for potential waivers of co-financing requirements as well as the implementation of a "Gavi Resilience Mechanism" – a dedicated fund of US$ 250 million set aside to address unforeseen needs in these settings, including outbreaks not covered by existing mechanisms such as stockpiles…

Enhanced support for African vaccine manufacturing

The Board confirmed enhanced support for sustainable African vaccine manufacturing, approving the use of an additional US$ 189 million – beyond the US$ 1 billion dedicated to Gavi's African Vaccine Manufacturing Accelerator (AVMA) – to strengthen demand for African-made vaccines and support critical ecosystem strengthening activities. The majority of this financing – US$ 139 million – will be dedicated to buying African-made vaccines, which will simultaneously supplement Gavi's vaccine procurement budget. An additional US$ 50 million in targeted financing will support three partners – the Africa Centres for Disease

Control and Prevention (Africa CDC), African Medicines Agency (AMA) and WHO – who will work together to address barriers to the accelerated development of a vaccine manufacturing ecosystem on the continent.

Appointment and process updates

- Dr Mekdes Daba was appointed Vice-Chair of the Gavi Board, effective 1 October 2026 and until 30 September 2028 – replacing Omar Abdi.
- Henry Gonzalez was appointed as an Unaffiliated Board Member, effective 1 November 2026 and until 31 October 2029, and Chair of the Investment Committee as of 1 November 2026 and until 31 December 2027, in both cases replacing Yibing Wu.
- Dr Mekdes Daba was appointed Chair of the Governance Committee, effective 1 October 2026 and until 31 December 2027 – replacing Omar Abdi.
- Dr Rana Hajjeh was appointed Chair of the Independent Review Committee (IRC) for a three-year term, effective immediately – replacing Dr Rose Leke.

::::::::

Gavi launches new supply chain strategy to boost vaccine availability and reach remote communities
1 July 2026
:: New immunisation Supply Chain Strategy seeks to build on recent years' momentum and help countries ensure vaccines reliably reach people safely, reliably and on time – including under-served communities.
:: Efforts in areas such as real-time cold chain monitoring are helping protect more than US$ 1.7 billion worth of vaccines each year, with one in six children globally benefitting, while private sector partnerships are improving efficiency and delivery performance.
:: Through closer alignment of systems and operations, Gavi and partners are implementing a "merger at the last mile," where global health initiatives bring together their distinct activities into a unified approach.

::::::::
::::::::

CEPI – Coalition for Epidemic Preparedness Innovations [04 Jul 2026]
http://cepi.net/
News
New experts appointed to CEPI's Scientific Advisory Committee
30th June 2026
New members appointed to the SAC
Eight experts have been appointed following a review process based on expertise, experience, and global representation:

- Dr Vaseeharan Sathiyamoorthy - World Health Organization (WHO), Switzerland
- Dr Marco Cavaleri - European Medicines Agency (EMA), The Netherlands
- Dr Lin H. Chen - Mount Auburn Hospital and Harvard Medical School, USA
- apl. Professor Dr Klaus Cichutek - Former President, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany
- Dr Joseph D. Santangelo - Takeda Pharmaceuticals, USA
- Professor Petro Terblanche - Afrigen Biologics, South Africa
- Dr Joanke Graveland-Bikker - Independent Consultant, The Netherlands
- Dr William Warren - WKLW Consulting LLC, USA

Five members have been reappointed following completion of their current term:

- Dr Rick A. Bright – Bright Global Health, USA

- Assistant Professor Yunlong Cao – Peking University, China
- Professor Amine Kamen – McGill University, Canada
- Dr Lynda Stuart – Independent Consultant, USA
- Professor George Warimwe – KEMRI-Wellcome Trust Research Programme, Kenya and University of Oxford, United Kingdom

A full list of CEPI's SAC members can be found here. CEPI is grateful to the SAC members completing their term and for their contributions to helping CEPI deliver on its mission.

::::::::
::::::::

"Wildlife Health"

WOAH launches Wildlife Health Strategy 2026–2030 to strengthen prevention, surveillance systems and rapid response capacities
World Organisation for Animal Health
News 3 July 2026
During its 93rd General Session in May, the World Organisation for Animal Health (WOAH) has launched its new Wildlife Health Strategy 2026–2030, to **reaffirm the importance of wildlife health surveillance systems as a cornerstone of global health security , biodiversity conservation and resilient ecosystems under an integrated health approach.**

Following the achievements of the Wildlife Health Framework (2021–2025), the new Strategy outlines a more focused and operational roadmap to support WOAH Members in preventing, detecting and responding to health risks at the human, animal, environment interface.

In a context marked by increasing interactions between humans, domestic animals and wildlife, WOAH is positioning wildlife health as a strategic global priority.

The Strategy is organised around three main objectives to strengthen governance of wildlife health systems, improve scientific knowledge and risk analysis based policies and sustainable, integrated multisectoral wildlife heath surveillance systems, **this new Strategy has focus areas on surveillance systems, addressing health risk in wildlife trade and support upstream prevention efforts to reduce the risk of disease emergence**…

WOAH Wildlife Health Strategy 2026-2030
[Excerpt]
WOAH Wildlife Health Strategy (2026–2030): Vision and Strategic Intent
The vision: Healthy animals, resilient ecosystems and a safer planet
In an era of increasing pressures driven by land-use change, climate change, illegal or unsustainable wildlife trade and intensifying human–animal (both wild and domestic)–environment interactions, promoting wildlife health and strengthening wildlife health resilience are essential to preventing disease emergence, protecting wildlife biodiversity and safeguarding global health.

The impact: WOAH, its Members and health networks are empowered to protect wildlife health
WOAH is committed to advancing a holistic and preventive approach to animal health that **fully integrates wildlife within the broader One Health approach**. This requires strengthened collaboration between Veterinary Services, public health authorities, environmental agencies and conservation actors to address health risks at their source. While Veterinary Services remain central to the prevention and management of animal disease risks, their effectiveness depends on stronger

multisectoral coordination, adequate capacities and enabling regulatory frameworks. **The WHS therefore aims to support Members in embedding wildlife health within national systems, including surveillance, legislation and risk management mechanisms**, in alignment with the WOAH 8th Strategic Plan (2026–2030) [3].

Building on existing partnerships and global collaborations, the WHS focuses on delivering practical, scalable solutions that translate international standards and guidance into operational impact at country level. Priority areas include strengthening integrated wildlife health surveillance systems, addressing health risks associated with legal and illegal wildlife trade, including animal welfare considerations, and understanding and mitigating the impacts of climate change on wildlife health, as well as the contribution of healthy wildlife to climate change mitigation.

Through a multisectoral, preventive and upstream-oriented approach, **the WHS seeks to enhance ecosystem resilience, improve preparedness and early detection capacities, and contribute to reducing the risk of disease emergence at the human–animal (both domestic and wild)–environment interface.**

** Official partners include the International Union for Conservation of Nature (IUCN), the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), the Wildlife Disease Association (WDA), the International Council for Game and Wildlife Conservation (CIC), the Quadripartite organisations, the Wildlife Health Intelligence Network (WHIN), The Convention on the Conservation of Migrating Species of Wild Animals (CMS), the Collaborative Partnership on Sustainable Wildlife Management (CPW), The Convention on Biological Diversity (CBD), the World Wildlife Fund (WWF).*

::::::::
::::::::
::::::::

Ebola – Bundibugyo virus disease (BVD) – PHEIC/PHECS

WHO

Disease Outbreak News (DONs)
Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda
3 July 2026
Situation at a glance
The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo continues to evolve rapidly, with sustained transmission and increasing numbers of reported cases. As of 1 July, a cumulative of 1460 confirmed cases, including 452 deaths, have been reported from the Democratic Republic of the Congo. As of 2 July, Uganda has reported 20 confirmed cases including two deaths, as well as one probable case who has died. In addition, on 24 June 2026, French authorities notified WHO of a laboratory-confirmed case of Ebola disease caused by Bundibugyo virus in a medical doctor returning from the Democratic Republic of the Congo. In Uganda, the outbreak remains epidemiologically linked to transmission originating in the Democratic Republic of the Congo, with evidence of both imported infections and secondary transmission among contacts and healthcare workers. Uganda has not reported any new cases since 21 June 2026. National authorities in the two affected countries, in collaboration with WHO and partners, are implementing an extensive set of response measures. A regional preparedness and prioritization framework continues to guide readiness activities across the African Region…

[Excerpts]

WHO risk assessment

On 6 June 2026, WHO reassessed the risk of the outbreak of BVD to incorporate newly available information and align with the WHO Temporary Recommendations. The risk for countries sharing land borders with countries with documented Bundibugyo virus (BVDV) detection, currently the Democratic Republic of the Congo and Uganda, has been separated out from the risk for other countries in the African Region.

The risk in the Democratic Republic of the Congo remains assessed as very high due to ongoing transmission and the continued expansion of the outbreak into new health zones, increasing the potential for further national and regional spread.

The risk in Uganda is assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor, historically affected by Ebola outbreaks, including Bundibugyo and Sudan virus disease outbreaks.

The risk for countries with land borders adjoining countries with documented BDBV detection is assessed as high due to sustained population mobility linked to cross-border trade and mining activities, variation in capacities and experience of BVD response, and variable levels of readiness.

The risk for the rest of the Africa region and at the global level is assessed as low.

For further information, please see the WHO Rapid Risk Assessment – Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo, Uganda and countries with land borders adjoining countries with documented BDBV detection v3.

WHO advice

WHO advises against any restriction of travel to, or trade with, the Democratic Republic of the Congo or Uganda based on the currently available information. WHO continues to closely monitor and, where necessary, verify travel and trade measures in relation to this event.

For further information on the considerations for implementing border health and international travel-related temporary recommendations, please see the relevant technical note issued on 26 May 2026.

The Temporary Recommendations issued to State Parties on 22 May 2026 underscore the importance of coordinated outbreak control, enhanced cross-border collaboration, and sustained surveillance and preparedness to prevent further regional spread and ensure an effective public health response.

WHO has convened several technical advisory groups, including the Strategic Advisory Group of Experts on Immunization (SAGE) to assess candidate vaccines and therapeutics for BVD. Key recommendations made are available in the news release published on 28 May 2026.

::::::::

WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing

2 July 2026 *News release*

Today, the World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL). **The test detects the virus by identifying its genetic material in blood samples, helping confirm infection rapidly and accurately.**

WHO's EUL procedure assesses the quality, safety and performance of essential health products based on the available evidence, while ensuring they meet minimum international standards and address the needs of low- and middle-income countries.

Through this mechanism, WHO aims to accelerate access to reliable diagnostic tools for early case detection, timely clinical care, disease surveillance and effective outbreak response. The EUL also supports United Nations procurement agencies and governments in making informed decisions about the procurement and use of these products in public health emergency settings…

::::::::

Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease

2 July 2026 *News release* Geneva/Oxford/Ituri

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.

The PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) trial will assess whether two antiviral therapies – a monoclonal antibody (MBP134) and remdesivir – can improve survival among people diagnosed with BVD. It will also evaluate whether combining the two antivirals provides additional benefits.

The trial, sponsored by the World Health Organization (WHO), has been coordinated **by the Institut National de Recherche Biomédicale (INRB) in the Democratic Republic of the Congo, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the United Kingdom**, in collaboration with international research, clinical and humanitarian partners, **and supported by Africa CDC…**

These treatments were selected for the trial by the WHO Technical Advisory Group after a thorough review of scientific evidence, including preclinical research and safety data, and evidence from previous outbreak responses. People enrolled in the clinical trial will be provided with close support and follow-up for at least 28 days after enrolment…

The trial has been established as a platform trial, which allows for additional treatments to be added as they become available following assessment by the WHO Technical Advisory Group…

The randomized, controlled trial is enrolling patients of any age with confirmed BVD. The participating treatment units will provide patients with early supportive care, including oral or intravenous fluids, electrolyte replacement, oxygen support, blood pressure management, and pain control in line with WHO treatment guidelines…

The trial is being delivered in partnership with the Ministry of Public Health of the Democratic Republic of the Congo, ALIMA (The Alliance for International Medical Action) and outbreak response teams from Médecins Sans Frontières (MSF). The study data will be regularly reviewed by an independent data and safety monitoring board.

The PARTNERS trial is expected to assess whether monoclonal antibodies and antiviral therapies can improve outcomes for patients with BVD and reduce mortality in affected communities. It is designed to operate seamlessly across multiple outbreaks, providing a sustainable research platform to generate evidence on safe and effective treatments for Ebola and Marburg diseases

::::::::
::::::::

Africa CDC

Community Engagement Should be Prioritised in Bundibugyo Ebola Outbreak Fight
3 July 2026
One month after the declaration of the 2026 Bundibugyo Ebola outbreak as both a global and continental public health emergency, **transmission continues to expand in eastern Democratic Republic of Congo (DRC) and Uganda despite substantial response efforts**. As of 14 June 2026, there were 827 confirmed cases and 194 deaths, with Ituri Province in DRC accounting for more than 91% of infections. Although 6,835 contacts have been identified, the relatively low case-to-contact ratio suggests that many transmission chains remain undetected.

The article in *Nature* argues that the outbreak is being sustained not only by epidemiological factors but also by insufficient community engagement. Because there are no highly effective vaccines or therapeutics for Bundibugyo Ebola virus disease, **outbreak control depends on fundamental public health measures such as early case detection, isolation, contact tracing, infection prevention and control, and safe burials.** These interventions are only effective when communities trust and actively participate in the response. Evidence of weak community trust includes patients leaving treatment or isolation facilities due to fear, misinformation, or dissatisfaction with care.

The authors argue that decentralizing outbreak response to the health zone and district levels is essential for making communities the driving force of Ebola control. Local actors and community leaders should be empowered to identify gaps, tailor interventions to local needs, combat misinformation, and build public trust.
Read more | https://www.nature.com/articles/s44360-026-00172-4

::::::::

In Kinshasa, President Tshisekedi Leads Ebola Response Push as President Ramaphosa Brings African Solidarity
2 July 2026
Africa CDC-convened engagement at INRB focuses on faster coordination, resource mobilisation and support to affected areas

KINSHASA, Democratic Republic of the Congo, 2 July 2026 – The President of the Democratic Republic of the Congo, H.E. Mr Félix Antoine Tshisekedi Tshilombo, today welcomed the President of the Republic of South Africa, H.E. Mr Cyril Ramaphosa, to the Institut National de Recherche Biomédicale in Kinshasa for a **high-level meeting focused on accelerating the Ebola response in the DRC and mobilising African support around the country**.

The meeting, convened by Africa CDC in support of the DRC authorities, **brought together the two Heads of State, Africa CDC Director General Dr Jean Kaseya, and senior representatives of the World Health Organization, the World Bank, the European Union, the United Kingdom and other partners engaged in the response.**

"The Government is closely monitoring the situation on a daily basis and is taking the necessary measures to protect our population, prevent the spread of the disease and preserve the health security of neighbouring countries," said President Félix Tshisekedi. **"This outbreak reminds us that health security is closely linked to peace and human security in areas affected by armed conflict.**

Insecurity weakens prevention, epidemiological surveillance and the capacity of public health actors to respond rapidly."

President Tshisekedi stressed that the simultaneous outbreaks in the DRC and Uganda demonstrate the need for a coordinated regional response based on shared responsibility. He also welcomed South Africa's continued support and thanked international partners, including South Africa, Africa CDC, the World Health Organization, UNICEF, the United States and China, for supporting the national response…

The political message of the meeting was strong: the DRC is leading the response, and the DRC is not alone.

The Minister of Health of the DRC presented the epidemiological situation and the immediate priorities of the national response. The Minister of Humanitarian Affairs outlined urgent needs in affected areas. Partners provided updates on support already deployed, commitments under way and remaining gaps.

Africa CDC presented the status of continental coordination, including actions taken with neighbouring countries to strengthen regional preparedness, support points of entry, improve surveillance and reduce the risk of cross-border spread…

The joint Africa CDC–WHO continental preparedness and response plan estimates Ebola and health response needs at US$518 million. Commitments announced exceed this amount, but only 21% of funds had been released according to data presented. The priority now is to turn commitments into rapid operational support for teams on the ground, affected communities, clinical trials, surveillance, laboratories, points of entry and regional preparedness.

"Ebola moves fast. Africa must move faster," said Dr Kaseya. "The financing exists. The commitments exist. They must now reach the places where they save lives."

::::::::
::::::::

Joint Statement

Accelerating Action for Pandemic Preparedness in 2026: Joint Statement by IPPS, CEPI, FIND, DNDi and Unitaid
June 30, 2026 ***UPDATE: 30th June 2026***
The ongoing Bundibugyo ebolavirus (BDBV) outbreak is a stark reminder that the global threat landscape is dynamic and unpredictable. It shows that future infectious disease and pandemic risks cannot be fully anticipated and that preparedness must extend within and across viral families, including those that are rare or historically neglected.

Despite significant progress made since the 2014–2016 Ebola outbreak, this BDBV outbreak exposes persistent gaps in research and development, limited surge capacity, and the absence of ready-to-deploy medicines, vaccines or diagnostics – as set out in the 100 Days Mission BDBV tracker. These weaknesses slow our ability to respond at scale. Africa CDC and WHO's joint continental preparedness and response plan demonstrates strong regional leadership and provides an important foundation for coordinated action. We also welcome the recent commitment by G7 leaders to a unified response to BDBV, as well as the forthcoming G20 discussions in October, which together signal growing political momentum. This creates a critical window to convert political attention into sustained, practical action.

The UN High-Level Meeting Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR) should recognise BDBV as a clear example of why preparedness must be strengthened across emerging and re-emerging pathogens. It should broaden commitment to support and fund the necessary elements to accelerating the current response to save lives quickly, mitigate economic disruption, and make innovations accessible, while aligning on new multilateral goals and funding requests that enable the development, authorisation, manufacturing and equitable delivery of diagnostics, therapeutics and vaccines.. This should include access conditions built into the R&D process as a key design feature, not an afterthought, immediate access to pipeline candidates for clinical trials, and robust post-trial access commitments.

As reminded by the 100 Days Mission, this is urgent and such commitments are critical to translate political intent into practical action and financing. We must ensure systems and funding mechanisms are in place to rapidly generate evidence about and scale new tools for current and future outbreaks. We stand ready to support Member States with technical expertise throughout the negotiations to help deliver an ambitious, actionable and implementable Political Declaration.

::::::::

Ebola (Bundibugyo) Day 45 – Tracking Progress on Medical Countermeasures
IPPS July 1, 2026
Day 45 of the 100 Days Mission Ebola Clock (major update)
The 100 Days Mission (100DM) clock for Bundibugyo ebolavirus (BDBV) started on 18 May 2026, following WHO's declaration of the outbreak as a public health emergency of international concern (PHEIC). Africa CDC declared a Public Health Emergency of Continental Security (PHECS) the following day.

Leading up to Day 100 on 25 August, we continue to provide updates every 15 days (alternating between minor and major updates) on the status and progress of BDBV diagnostics, therapeutics and vaccines (DTVs) availability and highlight immediate priority actions to ensure products can be rapidly evaluated, manufactured, deployed, and equitably accessed by affected communities.

On Day 45, we provide our latest major update on the status of BDBV diagnostics, therapeutics and vaccines. **This update also includes a deep dive on the Expression of Interest (EOI) process for diagnostic candidates and the Emergency Use Listing (EUL) pathway and highlights the priority actions needed to ensure products can be rapidly evaluated, manufactured, and equitably accessed.**

These updates are intended to support the work of partners and key initiatives and are developed in consultation with implementing partners of the 100DM. We are open to feedback on the accuracy of our data; please get in touch (info@ippsecretariat.org) if you have information to share.

The data used to inform this update has been collected through desk research using public information and direct updates from implementing partners of the 100DM.
Previous updates:
:: Day 0 statement
:: Day 15 (major update)
:: Day 30 (minor update)

[Excerpt]
…***Vaccines***

DAY 45
EBOLA BUNDIBUGYO VIRUS OUTBREAK
1st July 2026

100 Days Mission BDBV Tools Tracker

Status of vaccines

This overview is not exhaustive. See our full disclaimer on our Day 45 update at: bit.ly/EbolaBDBV-Day45

IPPS

Candidate *Developer*	Platform	Approvals for BDBV	BDBV evidence	Clinical-grade material	Clinical trials relevant to BDBV underway*	Notes
EXISTING LICENSED VACCINES (ZAIRE EBOLAVIRUS)						
Ervebo *MSD (rVSV-ZEBOV)*	rVSV	✗ Approvals for Zaire ebolavirus only	NHP data Partial, non-sterilising protection against BDBV (data generated with research-grade vaccine candidates, not licensed Ervebo product)	✓	N/A WHO SAGE does not recommend for programmatic use in this outbreak	• Existing data shows potential cross-protection; further evidence required to tie to efficacy • NHP model not 100% lethal • Data collected with research-grade rVSV vaccine candidates, not licensed Ervebo product
Zabdeno / Mvabea *Janssen (Ad26/MVA)*	Ad26 + MVA	✗ Marketing Authorisation for Zaire ebolavirus withdrawn in EU	✗ Immunogenicity studies: no meaningful immune response	Status unknown; for experimental use only	N/A WHO SAGE does not recommend for programmatic use in this outbreak	• Limited data on potential cross-protection in human recipients, showing little cross reactivity • Marketing authorisation withdrawn in EU
BDBV-SPECIFIC CANDIDATES (PRECLINICAL)						
rVSV-BDBV-GP *IAVI*	rVSV	✗	NHP data 100% protection (pre-exposure) 83% protection (post-exposure)	Not available	0 Ph I, Ph II, Ph III, Ph IV	• Most robust preclinical data currently • Small sample size for NHP data • NHP model is not 100% lethal (20-30% survival) • WHO TAG prioritised for near-term evaluation • CEPI-supported
rVSV-BDBV (PHAC) NEW *Public Health Vaccines / PHAC*	rVSV	✗	✗ Preclinical data pending	Not available	0 Ph I, Ph II, Ph III, Ph IV	• Platform licensed from Public Health Agency of Canada • BARDA-supported
rVSV-BDBV (PHV) NEW *Public Health Vaccines / NIAID (Marzi/Feldmann)*	rVSV	✗	NHP data 100% protection (pre-exposure, 3 or 7 days)	Not available	0 Ph I, Ph II, Ph III, Ph IV	• BARDA and CEPI supported • NHP model is not 100% lethal (20-30% survival)
ChAdOx1-BDBV *Oxford / Serum Institute of India*	ChAdOx1	✗	✗ Preclinical data pending	Dose manufacturing complete, pending release for clinical trials SII to produce clinical-grade material	0 Ph I, Ph II, Ph III, Ph IV	• Fastest potential path to clinical trial • Preclinical data limited • WHO TAG prioritised for near-term evaluation • CEPI-supported
mRNA-LNP-BDBV-GP *Moderna*	mRNA-LNP	✗	✗ Preclinical data pending	In production	0 Ph I, Ph II, Ph III, Ph IV	• mRNA platform offers rapid scale-up potential • Preclinical data limited • Manufacturing route established • CEPI-supported

[*Graphic in report not scaled for readability*]

On day 45, there are no approved vaccines for Bundibugyo virus disease. The only licensed Ebola vaccine, Ervebo®, is indicated for Zaire ebolavirus only. WHO SAGE does not recommend Ervebo® for use outside controlled research settings in response to the current outbreak, in light of limited and inconclusive evidence on cross-protection of rVSV-vectored Zaire ebolavirus vaccines against BDBV.

The Bundibugyo-specific vaccine pipeline remains at an early stage, with no candidates yet available for deployment in clinical trials, and no Bundibugyo-specific vaccine expected to be available for near-term outbreak deployment. A WHO Technical Advisory Group (TAG) has prioritised two candidates for near-term evaluation: rVSV-BDBV-GP (IAVI), assessed as the most promising single-dose option for post-exposure use, and ChAdOx1-BDBV (Oxford University/Serum Institute of India), the first candidate to complete clinical-grade production – manufacturing of doses is now complete and pending release for clinical trials. CEPI is funding accelerated development of both prioritised candidates, including Master Virus Seed stock generation, clinical-grade manufacturing, and Phase 1 clinical trial preparation https://cepi.net/cepi-fast-tracks-three-bundibugyo-ebolavirus-vaccine-candidates.

In addition, CEPI has committed up to $50 million to an mRNA-LNP candidate developed by Moderna, supporting preclinical testing, Phase 1 trials, and simultaneous manufacturing of doses at scale to enable Phase 2/3 trials to begin immediately if Phase 1 data supports progression. BARDA has additionally awarded funding to Public Health Vaccines for two further rVSV-vectored BDBV vaccine candidates – one developed in collaboration with the Public Health Agency of Canada, and a second based on research at NIAID, with CEPI co-funding Master Viral Seed stock generation for the latter https://www.phvaccines.com/downloads/Press%20Release-Jun-26.pdf.

CEPI's calls for proposals – to advance early-stage BDBV candidates toward Phase 1 evaluation, and to support evidence generation through epidemiological modelling and assessment of cross-protection from existing ebolavirus vaccines – closed in June, with selections pending https://cepi.net/calls-for-proposals?selectedProposal=1779. CEPI's request for information on Phase 1 clinical trial capacity across Africa, and BARDA's request for project proposals under the BundiVx Programme https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/, also closed in

June; outcomes are awaited. UNICEF and Gavi have issued a joint Expression of Interest seeking information from vaccine developers on plans to advance BDBV candidates through to licensure, with a view to establishing advance purchase commitments and supporting emergency dose availability, backed by Gavi's $40 million First Response Fund allocation…

::::::::
::::::::
::::::::

Polio – PHEIC

Polio this week [01 July 2026]
Headlines [Selected]
:: Global Polio Eradication Initiative High-Level Interview: WHO Director-General Dr Tedros Adhanom Ghebreyesus
In the first of a series of high-level interviews, WHO Director-General Tedros Adhanom Ghebreyesus shares his views on the global fight against polio.
:: Protecting the future: keeping mothers and children healthy during humanitarian crises
One in four people around the world live in fragile settings. Increasing conflict, natural disasters and other complex factors are contributing to an unprecedented number of children and families living amid humanitarian crises. This contribution by UN Foundation experts reflects on what lessons must be learned to come together and forge solutions.

Summary of new polioviruses this week:
:: Afghanistan: one WPV1 case
:: Pakistan: six WPV1-positive environmental samples
:: South Sudan: two cVDPV1 cases

::::::::
::::::::

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: U.S. Immunization and Public Health Governance/Policy/Funding
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
:: Think Tanks
:: Public Consultations/Call for Inputs/Call for Papers

::::::::
::::::::

WHO & Regional Offices [04 Jul 2026]
https://www.who.int/news
Selected News/Announcements/Statements
3 July 2026 *Departmental update*
WHO Director-General meets HIV community leaders to reaffirm commitment to community leadership and meaningful engagement

3 July 2026 *Departmental update*
WHO launches first global database on the prevalence of sexually transmitted infections

The World Health Organization (WHO) has launched a new global database on the prevalence of sexually transmitted infections (STIs). The open-access database is the first global platform to provide consolidated, standardized and quality-assured STI prevalence data from low- and middle-income countries from 2010 onwards. It addresses long-standing challenges in accessing reliable country- and population-specific data related to STIs, by bringing together both published and unpublished evidence from diverse sources in one place.

"This database represents a first major step forward in our ability to understand the burden of sexually transmitted infections across diverse populations and settings," said Dr Tereza Kasaeva, Director of WHO's Department for HIV, TB, Hepatitis and STIs. "By making these data openly accessible, we are equipping countries and partners with the evidence needed to design targeted interventions, strengthen surveillance systems and accelerate progress towards reducing the global impact of STIs."…

2 July 2026 *News release*
WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing

2 July 2026 *News release*
Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease

1 July 2026 *Departmental update*
Global leaders gather in Paris for high-level G7 labelled ATACH meeting on climate and health

30 June 2026 *Departmental update*
Countries pave the way for stronger local production and health sovereignty

30 June 2026 *Departmental update*
WHO expands Health Inequality Monitoring Network, doubling global membership
Network grows to 24 leading institutions, strengthening countries' capacity to monitor and address health inequalities
30 June 2026 Departmental update

The World Health Organization (WHO) has expanded its Health Inequality Monitoring (HIM) Network, doubling membership from 12 to 24 institutions across all regions. The expansion marks a significant step in strengthening global capacity to monitor health inequities and support countries in advancing health equity and universal health coverage.

Launched by WHO in June 2025, the HIM Network brings together leading academic institutions, national statistical agencies and public health organizations to strengthen health inequality monitoring worldwide. The addition of new members broadens the Network's geographic reach and technical expertise, enhancing its ability to support countries in identifying populations being left behind and developing evidence-informed policies and interventions…

30 June 2026 *Departmental update*
Behavioural Sciences for Better Health: A WHO Toolkit for Institutional Capacity

30 June 2026 *Departmental update*
New WHO report outlines critical steps to confront fungal disease and antifungal resistance

29 June 2026 *Departmental update*
New SDG data shows stalled progress on air pollution and health

29 June 2026 *Note for Media*
Forty-ninth session of the FAO/WHO Codex Alimentarius Commission adopts new standards

29 June 2026 *Departmental update*
WHO certifies Turks and Caicos for eliminating mother-to-child transmission of HIV and hepatitis B

::::::::

WHO Vaccines and Immunization [IVB]
https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1
News
30 June 2026 *Departmental update*
Countries pave the way for stronger local production and health sovereignty
Indonesia's Minister of Health, H.E. Mr Budi Gunadi Sadikin, leads global discussions ahead of the Fourth World Local Production Forum in Bali in 2027
30 June 2026 *Departmental update*
As countries seek to strengthen preparedness for future health emergencies and improve access to essential health products, local and regional production is increasingly recognized as a cornerstone of equitable access, resilient health systems and global health security.
At a high-level side event during the Seventy-ninth World Health Assembly, ministers, policymakers, manufacturers and global health partners gathered to identify priority actions to advance the local production of vaccines, medicines, diagnostics and medical devices, particularly across low- and middle-income countries. Co-hosted by the Government of Indonesia and the Developing Countries Vaccine Manufacturers Network (DCVMN), with support from international partners, the event also marked an important milestone on the road to the Fourth World Local Production Forum (WLPF), which will take place in Bali, Indonesia, in 2027…

::::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: 01 July 2026
Zimbabwe strengthens health workforce to advance universal health coverage
:: 01 July 2026
In the frontlines of a safe and dignified Ebola outbreak response in Uganda
:: 29 June 2026
Kenya, Rwanda strengthen their defences against antimicrobial resistance

WHO Region of the Americas PAHO
:: 1 Jul 2026
As influenza rises across countries in the Southern Hemisphere, PAHO urges vaccination and stronger health system preparedness
The increase comes as the respiratory virus season begins and influenza, respiratory syncytial virus (RSV), and other viruses circulate simultaneously, potentially driving greater demand for health care services. Washington, D.C., July 1, 2026 (PAHO/WHO) — The Pan American Health Organization (PAHO/WHO) has warned of rising influenza activity in…
:: 1 Jul 2026
PAHO launches US$24 million appeal to support health response following devastating earthquakes in Venezuela

Washington, D.C., 1 July 2026 (PAHO) – The Pan American Health Organization (PAHO), the Regional Office for the Americas of the World Health Organization (WHO), has launched a US$24 million emergency appeal to support the first six months of the health response and early recovery following the devastating earthquakes that struck Venezuela on 24…
:: 30 Jun 2026
PAHO expands health response as Venezuela faces mounting health risks after devastating earthquakes
Caracas, Venezuela/Washington, D.C., 30 June 2026 (PAHO) – The Pan American Health Organization (PAHO) is expanding its support to Venezuela's Ministry of Health following the two powerful earthquakes that struck the country on 24 June, deploying technical experts, coordinating international Emergency Medical Teams (EMTs),

WHO South-East Asia Region SEARO
:: 2 July 2026 *News release*
WHO, Member States discuss expanding South-East Asia Regional Health Emergency Fund SEARHEF

WHO European Region EURO
:: 2 July 2026 *News release*
WHO releases new guidance on the repair, refurbishment and recycling of assistive technology
:: 1 July 2026 *Media release*
Preparing for the next big one: health ministers gather in Istanbul where scientists predict a major earthquake in the coming decades

WHO Eastern Mediterranean Region EMRO
No new digest content identified.

WHO Western Pacific Region
:: 1 July 2026 *Media release*
11 Western Pacific countries join WHO to launch regional road map and community of practic…
:: 30 June 2026
Asia–Pacific partners work together to support nationally led health emergency response

::::::

WHO - Emergency situation reports
Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.
No new digest content identified.

::::::::

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health
3 July 2026 | Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda

2 July 2026 | Hantavirus outbreak linked to cruise ship travel, Multi-locations
Situation at a glance

… All confirmed cases are among individuals who travelled onboard the M/V Hondius. Among the ten cases admitted to hospitals, eight have recovered and have been discharged, while two are still undergoing medical treatment. All identified contacts have completed the 42 day follow-up period by local health authorities in line with WHO guidance. **The completion of the contact follow up without detection of additional secondary cases demonstrates effective interruption of transmission and confirms outbreak containment. This outbreak no longer poses a public health risk and no further related transmission is expected.**

:::::::

Weekly Epidemiological Record

https://www.who.int/publications/journals/weekly-epidemiological-record
Volume 101 Issue 26 (22 June – 28 June 2026)
https://iris.who.int/server/api/core/bitstreams/9feeb722-799c-4a17-ab3d-879da5a9dc1d/content
:: Highlighted signals and events
:: Multi-country outbreak of cholera

:::::::

New WHO Publications

https://www.who.int/publications
Selected
2 July 2026
Regional Consultation on Vaccine and Immunization Research Preparedness for Vaccine Preventable Disease (VPD) Outbreaks and Pandemics, 14–16 April 2026, New Delhi, India
… the WHO South-East Asia Regional Office (SEARO) and CEPI co-hosted a three-day Regional Consultation from 14 to 16 April 2026 in New Delhi, bringing together more than 90 participants (both face-to-face and virtual) from all Member States, the SEARITAG, vaccine manufacturers, academic institutions, regulatory authorities, and development partners. The consultation aimed to strengthen vaccine and immunization research readiness during outbreaks and pandemics in the WHO South-East Asia Region by developing a framework for a responsive, well-governed, and collaborative immunization research ecosystem.

1 July 2026
Eighteenth Bi-regional meeting of National Influenza Centres and Influenza Surveillance in the WHO South-East…

1 July 2026
Regional Workshop on Human Resources for Health Strengthening Competence and Compassion

30 June 2026
Blueprint for strengthening responses to fungal disease and antifungal resistance
Overview
The Blueprint for strengthening responses to fungal disease and antifungal resistance Implementation guidance, provides a structured, operational framework to support countries and partners in strengthening coordinated responses to fungal disease and antifungal resistance (AFR).
Fungal diseases and AFR are associated with significant morbidity and mortality globally, yet remain under-recognized, underdiagnosed and under-resourced in many national and global health settings. Building on the WHO Fungal Priority Pathogens List and aligned with the Global Action Plan on Antimicrobial Resistance and other relevant WHO strategies and health system frameworks, the Blueprint responds to requests from Member States, regional bodies and global partners for practical guidance to operationalize global priorities and strengthen national and regional responses.

The guidance identifies critical gaps across awareness, workforce capacity, diagnostics, access to treatment, surveillance, stewardship and research — particularly in low- and middle-income countries — and presents integrated, equity-oriented and One Health approaches to help address them…

::::::::
::::::::
::::::::

Africa

Africa CDC [04 Jul 2026]
https://africacdc.org/
News & Updates [Selected]
Articles
Community Engagement Should be Prioritised in Bundibugyo Ebola Outbreak Fight
3 July 2026

Articles
Inspiring, shaping and sustaining an African research and development agenda
2 July 2026
In a commentary, a group of scientists on Africa has proposed the Africa Continental R&D Framework to provide a renewed, continent-wide strategy for strengthening Africa's health R&D capacity. Led by the Africa Centres for Disease Control and Prevention (Africa CDC) in collaboration with partners, the initiative aims to strengthen Africa's pandemic preparedness, improve health security, and accelerate progress toward universal health coverage through expanded local manufacturing.
Read More | https://www.nature.com/articles/s41591-026-04480-w

Press Releases
In Kinshasa, President Tshisekedi Leads Ebola Response Push as President Ramaphosa Brings African Solidarity
2 July 2026

::::::
::::::

China – CDC+

National Health Commission of the People's Republic of China [04 Jul 2026]
http://en.nhc.gov.cn/
News
No new digest content identified.

National Medical Products Administration – PRC [04 Jul 2026]
http://english.nmpa.gov.cn/
NMPA holds meeting on vaccine regulatory QMS
Updated: 2026-06-29
To advance the development of China's National Regulatory Authority (NRA) for vaccines and further enhance the country's vaccine regulatory capacity, the National Medical Products Administration (NMPA) held a working meeting on the development of the vaccine regulatory quality management system (QMS) in Changzhou, Jiangsu province, on June 12.

China CDC
***CCDC Weekly Reports*: Current Volume (8)**
https://weekly.chinacdc.cn/article/current
2026 Vol. 8 No. 27 PDF
:: **Mapping of the Global Importation Risk of Malaria to China — Global, 2024**
Conghui Duan, Zhigui Xia, Yuwan Hao, Jingbo Xue, Shizhu Li, Shang Xia
:: **Characterization of LCR7 Length Polymorphisms Across Lineages — Shenzhen City, Guangdong Province, China, 2023–2025**
Bo Peng, Ziquan Lyu, Wenxiao Gong, Xiaomin Zhang, Shiting Chen, Wenjuan Ma, Xiaolu Shi, Jia Wan, Jing Qu, Xiaoping Dong

::::::
::::::

Europe

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports/Publications [Selected]
Publications
Surveillance and monitoring
Communicable disease threats report, 27 June - 3 July 2026, Week 27
3 July 2026

Surveillance and monitoring
Seasonal surveillance of West Nile virus infections in humans and animals, monthly report
1 July 2026

European Medicines Agency [EMA]
https://www.ema.europa.eu/en/news
News & Press Releases
No new digest content identified.

::::::::
::::::::

India

National Centre for Disease Control
Directorate General of Health Services, Ministry of Health & Family Welfare
Announcements
No new digest content identified.

::::::::
::::::::
::::::::

U.S. Immunization and Public Health Governance/Policy/Funding
Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external

analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders; Memoranda; Proclamations
No new digest content identified.

Department of State

Press Releases - Selected
Press Statement

United States and Tanzania Advance Global Fight Against Infectious Diseases Through Bilateral Health Memorandum of Understanding

Thomas "Tommy" Pigott July 1, 2026

Today, the United States and Tanzania signed a five-year bilateral global health Memorandum of Understanding (MOU) through the Trump Administration's America First Global Health Strategy to save lives, advance shared global health goals, and bolster Tanzanian self-sufficiency to address infectious diseases and emerging health threats.

Building on decades of gains made through U.S. global health assistance to Tanzania, the United States and Tanzania will act as co-investors under this MOU, jointly building a durable network of hospitals, laboratories, and health care workers able to care for Tanzanians now and independently address public health threats of the future. The United States will direct assistance to support Tanzania's health priorities and help Tanzania tap into American expertise in pharmaceuticals, health innovation, and technology. Joint activities under this MOU aim to facilitate a sustainable transition from the previous donor-recipient model to a new partnership that will help Tanzania finance, manage, and sustain its health system over the long run, strengthening Tanzania's ability to detect and respond to infectious disease outbreaks. The five-year MOU also intends to sustain national control of HIV, malaria, polio, and tuberculosis, and meet the needs of Tanzania's growing population through supporting maternal and child health.

The United States, working with Congress, intends to provide more than $1.3 billion over five years under this MOU, and the United Republic of Tanzania intends to increase its domestic expenditures by $1.8 billion in national funds over the same time period….

As of July 1, the State Department has signed 34 bilateral global health MOUs with Angola, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Côte d'Ivoire, the Democratic Republic of the Congo, the Dominican Republic, El Salvador, Eswatini, Ethiopia, Guatemala, Guinea, Honduras, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mozambique, Niger, Nigeria, Panama, Papua New Guinea, the Philippines, Rwanda, Senegal, Sierra Leone, South Sudan, Tajikistan, Tanzania, and Uganda.

Media Note

Update on the Trump Administration's Robust and Rapid Delivery of Life-Saving U.S. Assistance to Venezuela

June 29, 2026

HHS

Press Room - Selected

HHS Secretary Kennedy Signs COVID-19 Emergency Use Authorization Declaration Terminations

WASHINGTON—JUNE 30, 2026—The U.S. Department of Health and Human Services (HHS) today announced that Secretary Robert F. Kennedy, Jr. has signed determinations terminating the COVID-19 Emergency Use Authorization (EUA) declarations for drugs and biological products and for medical devices, concluding that the circumstances that justified these emergency authorities no longer exist.

"Americans deserve a regulatory system that is transparent, accountable, and rooted in the rule of law," said HHS Secretary Robert F. Kennedy, Jr. "By ending these COVID-19 emergency use authorization declarations, we're reinforcing public confidence that emergency authorities are temporary and targeted."

The terminations will take effect following advance notice periods to ensure an orderly transition. The declaration for drugs and biological products will terminate 12 months after the Secretary's determination, while the declarations for medical devices will terminate 180 days after the Secretary's determination.

The COVID-19 EUA declarations were first issued in 2020 to enable rapid access to medical products during the pandemic. Since then, the public health landscape has changed substantially. FDA-approved, cleared, and licensed products are now widely available through traditional regulatory pathways, reliance on EUA products has declined, and manufacturers have had years to prepare for a transition from emergency authorities.

The advance notice periods are designed to provide manufacturers, healthcare providers, health systems, distributors, and patients adequate time to transition away from products authorized solely under the COVID-19 EUA declarations. During this transition, HHS and the Food and Drug Administration (FDA) will continue working with manufacturers on appropriate regulatory pathways for products seeking traditional approval, clearance, or licensure…

NIH

News Releases

NIH's All of Us Research Program now the world's largest integrated genomics and health database

June 30, 2026

Data from more than 747,000 participants is available to scientists, powering next-generation discoveries in precision medicine.

FDA

Press Announcements

July 1, 2026 - FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

FDA CBER

What's New for Biologics

07/02/2026	July 1, 2026 Approval Letter - FLUARIX
07/02/2026	SOPP 8417: Implementation and Management of Risk Evaluation and Mitigation Strategies (REMS)
07/02/2026	July 1, 2026 Approval Letter - Flublok
07/02/2026	July 1, 2026 Approval Letter - CASGEVY
7/02/2026	July 1, 2026 Approval Letter - FLUCELVAX
07/02/2026	July 1, 2026 Approval Letter - FLULAVAL
07/02/2026	July 1, 2026 Approval Letter - Fluzone and Fluzone High-Dose
07/02/2026	July 1, 2026 Approval Letter - FLUAD
07/01/2026	Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot CL6814 through December 31, 2026
07/01/2026	BK261345- HIV Combo Next Assay
07/01/2026	July 1, 2026 Approval Letter - TREGZI
06/30/2026	June 29, 2026 Approval Letter - AREXVY
06/29/2026	Important Information for Blood Establishments Regarding Ebola Disease and Blood Donation
06/29/2026	Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus; Guidance for Industry

06/29/2026 Cellular, Tissue, and Gene Therapies Advisory Committee Meeting Announcement
Date: July 29, 2026

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]
Advisory Committee Calendar
Vaccines and Related Biological Products Advisory Committee Meeting Announcement
Date: June 18, 2026
[YouTube recording here]

FDA Pediatric Advisory Committee Meeting
Advisory Committee Calendar
No future meeting dates posted.

CDC
http://www.cdc.gov/media/index.html
Latest News - Selected
No new digest content identified.

CDC – Immunization Safety Office (ISO)
https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html
No new digest content identified [last updated August 7, 2024]

ACIP
2026 Meetings Schedule
- March 18-19 (Due to ongoing litigation, this meeting is cancelled)
- June 24-26 (Due to ongoing litigation, this meeting is cancelled)
- October 21-23

National Vaccine Advisory Committee (NVAC)
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No 2025 or 2026 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)
https://www.hrsa.gov/advisory-committees/vaccines/meetings
Next ACCV meetings – TBD

MMWR Weekly
https://www.cdc.gov/mmwr/index2026.html
July 2, 2026 / No. 25
PDF of this issue
No new digest content identified.

::::::::

National Science Foundation/NSF
News
No new digest content identified.

::::::::

U.S. Congress
House

No new digest content identified.

Senate
No new digest content identified.

::::::::

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]
https://litigationtracker.law.georgetown.edu/
No new digest content identified.

::::::::
::::::::
::::::::

U.S. Medical, Scientific, Professional Societies; Health Organizations
This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)
https://www.aafp.org/news/media-center.html
(Accessed 04 Jul 2026)
No new digest content identified.

American Academy of Pediatrics (AAP)
https://www.aap.org/en/news-room/news-releases-from-the-aap/
(Accessed 04 Jul 2026)
News
No new digest content identified.

American College of Physicians (ACP)
https://www.acponline.org/more-acp-news
(Accessed 04 Jul 2026)
ACP News
Same day administration of COVID-19 and influenza vaccines not associated with increase in adverse events
07/01/26
Annals of Internal Medicine

America's Health Insurance Plans (AHIP)
https://www.ahip.org/news
(Accessed 04 Jul 2026)
News
No new digest content identified.

American Geriatrics Society (AGS)
https://www.americangeriatrics.org/media-center

(Accessed 04 Jul 2026)
Recent Press Releases
No new digest content identified.

American Medical Association (AMA)
https://www.ama-assn.org/press-center
(Accessed 04 Jul 2026)
Press Releases
No new digest content identified.

American Osteopathic Association (AOA)
https://osteopathic.org/news/
(Accessed 04 Jul 2026)
Latest News
No new digest content identified.

American Public Health Association (APHA)
https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc
(Accessed 04 Jul 2026)
No new digest content identified.

Infectious Diseases Society of America (IDSA)
https://www.idsociety.org/
(Accessed 04 Jul 2026)
Statement on request for funding Ebola response
Last Updated June 29, 2026
Additional funding to address the Ebola epidemic in Central Africa is critically needed to save lives and contain the current outbreak. The Administration's request for this funding is an important step in restoring the United States' reputation as a global leader in protecting people from infectious diseases.
However, providing funds solely to the State Department fails to reflect the reality that responding to an outbreak requires coordination across many agencies, including the Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases, and the Administration for Strategic Preparedness and Response. These agencies provide the scientific expertise needed to ensure that investments in the Ebola response have the greatest possible impact.
— Ronald G. Nahass, MD, MHCM, FIDSA – President, IDSA

National Foundation for Infectious Diseases (NFID)
https://www.nfid.org/news-updates/
(Accessed 04 Jul 2026)
News and Updates
NFID Announces Launch of Measles Collaborative and Appointment of Executive Director
Bethesda, MD (July 1, 2026)—The National Foundation for Infectious Diseases (NFID) is pleased to announce the creation of the Measles Collaborative, a new initiative established following the successful Measles Summit convened by NFID in partnership with the Infectious Diseases Society of America (IDSA) in May 2026.

The Measles Summit convened 15 US medical societies, public health organizations, and measles subject matter experts to identify high-priority opportunities for coordinated action. The Measles Collaborative translates those priorities into collective action. As of June 25, 2026, with 2,134 confirmed measles cases reported by 39 states and the District of Columbia, the US is poised to surpass last year's record of 2,288 confirmed cases. Working across 8 dedicated workgroups, the Collaborative aims to strengthen measles prevention, response, and education nationwide through a broad portfolio of planned initiatives and resources. Founding societies will also engage additional partners to support and expand the Collaborative's work.

The Collaborative is guided by an Executive Steering Committee that includes founder Ruth Lynfield, MD; NFID CEO Rebecca Alvania, PhD, MA, MPH; Pia Pannaraj, MD, MPH, of the University of California San Diego; and Pediatric Nurse Practitioner Patricia (Patsy) A. Stinchfield, PNP, former NFID President.

NFID is also pleased to announce the appointment of Patsy Stinchfield, PNP, as Executive Director of the Measles Collaborative…

June 29, 2026
Vaccine Confidence Strategies and Emerging Vaccinology Science

With vaccine confidence top of mind for many infectious disease experts, the 2026 Annual Conference on Vaccinology Research covered communication challenges as well as the latest in vaccine science.

National Medical Association (NMA)
https://nmanet.org/blog/
(Accessed 04 Jul 2026)
Latest News
No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)
https://pids.org/news-announcements/
(Accessed 04 Jul 2026)
News & Announcements
No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)
https://shea-online.org/news/
(Accessed 04 Jul 2026)
No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)
https://www.smfm.org/
(Accessed 04 Jul 2026)
News
No new digest content identified.

::::::::
::::::::

Civil Society – Individuals, Organizations, Institutions *[Selected]*

::::::::

Kaiser Family Foundation/KFF [04 Jul 2026]
https://www.kff.org/search/?post_type=press-release
Research, Analysis
KFF Tracker: America First MOU Bilateral Global Health Agreements
Jul 1, 2026 *Tracker*
This tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.

KFF Tracking Poll on Health Information and Trust: Update on Common Vaccine Myths
Jun 30, 2026 *Poll Finding*
This poll looks at exposure to and belief in several vaccine myths and finds that people without a trusted health care provider, and those who regularly use social media or AI for health information, are generally more likely than others to belief the false claims. It also analyzes belief across vaccine myths, showing the share of the public that are consistent myth believers, consistent myth deniers, and those who land in the "mixed middle."

::::::::

Vaccine Integrity Project – CIDRAP [to 04 Jul 2026]
https://www.cidrap.umn.edu/vaccine-integrity-project
Announcements, Viewpoints
No new digest content identified.

::::::::

Center for Vaccine Ethics & Policy - GE2P2 Global Foundation [to 04 Jul 2026]
https://centerforvaccineethicsandpolicy.net/
No new digest content identified.

::::::::

Paul Offit, MD – *Beyond the Noise*
Substack: https://pauloffit.substack.com/
No new digest content identified.

::::::
::::::

Contents [click to move among sections]

:: *Milestones, Perspectives*
:: *WHO*
:: *Organization Announcements*
:: *Journal Watch*
:: *Pre-Print Servers*

::::::
::::::

Organization Announcements

Paul G. Allen Frontiers Group [04 Jul 2026]
https://alleninstitute.org/news-press/
News
No new digest content identified.

Gates Foundation [04 Jul 2026]
https://www.gatesfoundation.org/ideas/media-center
Press Releases & Statements
No new digest content identified.

CARB-X [04 Jul 2026]
https://carb-x.org/
News
No new digest content identified.

Chan Zuckerberg Initiative [04 Jul 2026]
https://chanzuckerberg.com/newsroom/
Newsroom
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [04 Jul 2026]
http://cepi.net/
News
New experts appointed to CEPI's Scientific Advisory Committee
30th June 2026
New members appointed to the SAC
Eight experts have been appointed following a review process based on expertise, experience, and global representation:
- Dr Vaseeharan Sathiyamoorthy - World Health Organization (WHO), Switzerland
- Dr Marco Cavaleri - European Medicines Agency (EMA), The Netherlands
- Dr Lin H. Chen - Mount Auburn Hospital and Harvard Medical School, USA
- apl. Professor Dr Klaus Cichutek - Former President, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany
- Dr Joseph D. Santangelo - Takeda Pharmaceuticals, USA
- Professor Petro Terblanche - Afrigen Biologics, South Africa
- Dr Joanke Graveland-Bikker - Independent Consultant, The Netherlands
- Dr William Warren - WKLW Consulting LLC, USA

Five members have been reappointed following completion of their current term:
- Dr Rick A. Bright – Bright Global Health, USA
- Assistant Professor Yunlong Cao – Peking University, China
- Professor Amine Kamen – McGill University, Canada
- Dr Lynda Stuart – Independent Consultant, USA
- Professor George Warimwe – KEMRI-Wellcome Trust Research Programme, Kenya and University of Oxford, United Kingdom

A full list of CEPI's SAC members can be found here.

CEPI is grateful to the SAC members completing their term and for their contributions to helping CEPI deliver on its mission.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 04 Jul 2026]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [04 Jul 2026]
https://www.darpa.mil/news
News
No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [04 Jul 2026]
https://dndi.org/press/press-releases/
Press Releases
No new digest content identified.

Duke Global Health Innovation Center [04 Jul 2026]
https://dukeghic.org/
News
No new digest content identified.

EDCTP [04 Jul 2026]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
01 July 2026
Developing Africa's next generation of epidemic modellers through TIMERA
The Training Initiative for Modelling Epidemic Response in Africa (TIMERA) has been awarded a €1.3 million grant under the Global Health EDCTP3 programme to strengthen mathematical and statistical modelling capacity across sub-Saharan Africa. The project aims to enhance public health event detection, scenario planning, and outbreak response through advanced epidemiological modelling and data-driven decision-making.

30 June 2026
EDCTP Association welcomes new Board members

Emory Vaccine Center [04 Jul 2026]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [04 Jul 2026]

http://www.euvaccine.eu/
News
EVI joins call for sustained EU investment in global health research ahead of FP10
Eight Product Development Partnerships, including the European Vaccine Initiative, have published a joint advocacy paper urging EU Member States to ensure continued and strengthened funding for the Europe & Developing Countries Clinical Trials Partnership (EDCTP) under the 10th EU Framework Programme for Research and Innovation (FP10). 29 June 2026 The paper, Advancing Global Health Innovation Through Europe-Africa Collaboration, makes the case that sustained investment in ED

Fondation Merieux [04 Jul 2026]
http://www.fondation-merieux.org/
Actualités
No new digest content identified.

Gates Medical Research Institute [04 Jul 2026]
https://www.gatesmri.org/news
News: Articles and Publications
No new digest content identified.

Gavi [to 04 Jul 2026]
https://www.gavi.org/
News Releases, VaccinesWork
2 July 2026
Gavi Board meeting underlines commitment to country sovereignty, fragility and health security

1 July 2026
Gavi launches new supply chain strategy to boost vaccine availability and reach remote communities

GE2P2 Global Foundation [04 Jul 2026]
www.ge2p2.org
News/Analysis/Publications-Digests/Statements/Digests
**:: Vaccines and Global Health: The Week in Review - ** Current edition
:: Public Consultations Watch :: Global Calls for Input/Public Comment – 19 June 2026

GHIT Fund [04 Jul 2026]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

Global Fund [to 04 Jul 2026]
https://www.theglobalfund.org/en/news/
News Releases
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [04 Jul 2026]
https://www.glopid-r.org/
News & Event
No new digest content identified.

Hilleman Laboratories [04 Jul 2026]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [04 Jul 2026]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [04 Jul 2026]
https://www.humanimmunomeproject.org/
News
No new digest content identified.

IAVI [04 Jul 2026]
https://www.iavi.org/
Press Releases, Features
June 2026
Advancing Global Health Innovation through Europe-Africa Collaboration
Eight Product Development Partnerships (PDPs) are joining forces to call for sustained investment in the European and Developing Countries Clinical Trials Partnership (EDCTP) under the next EU Framework Programme for Research and Innovation and other EU funding frameworks under discussion.

INSERM [04 Jul 2026]
https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 04 Jul 2026]
https://www.ich.org/
News/Pubs/Press Releases [Selected]

No new digest content identified.

ICRC [to 04 Jul 2026]
https://www.icrc.org/en/news
Latest press releases and statements
Sudan: 42,000 people assisted with food in Al Obeid amid growing humanitarian needs
News release 02-07-2026

Article 02-07-2026
ICRC Hosts High-Level Dialogue with Diplomatic Community on Cyber Warfare and IHL
How is cyber warfare testing humanitarian law? The International Committee of the Red Cross (ICRC) delegation to the African Union (AU), with the embassies of Switzerland and Ghana, hosted a high-level dialogue on protecting civilians as warfare becomes increasingly digital.

IFFIm [04 Jul 2026]
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 04 Jul 2026]
http://media.ifrc.org/ifrc/news/press-releases/
Press releases
El Niño underway in Asia Pacific, Red Cross Red Crescent steps up early action to protect millions at risk
30/06/2026 | *Press release*

IPPS - International Pandemic Preparedness Secretariat [04 Jul 2026]
https://ippsecretariat.org/news/
News
Ebola (Bundibugyo) Day 45 – Tracking Progress on Medical Countermeasures
July 1, 2026

Accelerating Action for Pandemic Preparedness in 2026: Joint Statement by IPPS, CEPI, FIND, DNDi and Unitaid
June 30, 2026

Institut Pasteur [04 Jul 2026]
https://www.pasteur.fr/en/press-area
Press Documents
No new digest content identified.

InterAcademy Partnership (IAP)
https://www.interacademies.org/news/press-releases
News
No new digest content identified.

ISC / International Science Council [to 04 Jul 2026]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations *including Academies and Research Councils.*
blog
02 July 2026 - 9 min read
Organized science in the age of AI: Are we asleep at the wheel?

news
30 June 2026 - 10 min read
Call for nominations of experts to review the 2027 Global Sustainable Development Report | deadline: 31 July 2026

news
30 June 2026 - 6 min read
Launch of a global mentorship scheme to support displaced scholars

International Union of Immunological Societies (IUIS)
https://iuis.org/
News, Resources
IUIS has approved adoption of the SAGER guidelines
July 2, 2026
IUIS is pleased to announce its adoption of the Sex and Gender Equity in Research (SAGER) guidelines, joining a growing number of organizations committed to systematically integrating sex and gender considerations into the design, analysis, and reporting of research in line with international best practices.

IVAC [04 Jul 2026]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
June 29, 2026
Sustaining the Gains in Childhood Vaccination in the U.S.
In March 2026, the International Vaccine Access Center (IVAC) brought together key partners from jurisdictions across the United States to discuss recent challenges facing immunization programs and develop actionable strategies to strengthen immunization systems and sustain childhood vaccination coverage.

IVI [04 Jul 2026]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified

Johns Hopkins Center for Health Security [04 Jul 2026]
https://centerforhealthsecurity.org/newsroom
Center News [Selected]
No new digest content identified.

Robert Wood Johnson Foundation [to 04 Jul 2026]
https://www.rwjf.org/en/about-rwjf/newsroom.html
Latest News and Highlights
Statement from Richard Besser, MD, on Protecting Birthright Citizenship
Statement Jun-30-2026 Richard Besser

MSF/Médecins Sans Frontières [to 04 Jul 2026]
http://www.msf.org/
Latest [Selected Announcements]
Philippines
Communities in Mindanao receive medical support following earthquake in the Philippines
Project Update 3 Jul 2026

Venezuela
How MSF is responding to the earthquakes in Venezuela
Project Update 1 Jul 2026

National Academy of Medicine - USA [to 04 Jul 2026]
https://nam.edu/programs/
News, Stories, Insights
Jul 1, 2026 *Announcement*
NAM Welcomes Monica M. Bertagnolli as President
Monica M. Bertagnolli, MD, began a 6-year term as president of the National Academy of Medicine on July 1, 2026. She will also serve as Vice Chair of the National Research Council, which houses the majority of programs within the National Academies of Sciences, Engineering, and Medicine…

National Academies-Sciences-Engineering-Medicine [NASEM] - USA [to 04 Jul 2026]
https://www.nationalacademies.org/newsroom
News
News Release
New NAS and NAM Presidents Take Office
Last update July 1, 2026
WASHINGTON — Renowned evolutionary biologist Neil H. Shubin took office today as the president of the National Academy of Sciences. Also today, Monica M. Bertagnolli, former director of the National Institutes of Health, began as president of the National Academy of Medicine…

PATH [04 Jul 2026]
https://www.path.org/media-center/
Newsroom [Selected]
No new digest content identified.

Sabin Vaccine Institute [04 Jul 2026]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [04 Jul 2026]
http://www.unaids.org/en
News, Stories, Updates
Press Release
Planning for the future at UNAIDS' 58th Board meeting
GENEVA, 2 July 2026—Just one week after Member States adopted a new Political Declaration on HIV/AIDS at the United Nations General Assembly in New York, the 58th Programme Coordinating Board (PCB) took the next step in shaping how the Joint United Nations Programme on HIV/AIDS (UNAIDS) will evolve to help deliver those commitments.
Building on the renewed global political commitment to end AIDS as a public health threat by 2030, Board members reaffirmed the need for a strong, coordinated global HIV response while advancing discussions on how the Joint Programme should accompany the global response in a changing financial and global health landscape...

Press Statement
UNAIDS supports efforts to protect the continuity of the HIV response during the emergency in Venezuela
CARACAS/PANAMA CITY, 2 July 2026—UNAIDS mourns the tragic loss of life and expresses solidarity with the people and communities affected by the devastating earthquakes that struck Venezuela on 24 June. UNAIDS reaffirms its commitment to supporting efforts to ensure the continuity of HIV-related services during the emergency.
"The disruption of health services and population displacement caused by the disaster have created significant challenges for people living with HIV and other vulnerable populations," said Luisa Cabal, UNAIDS Regional Director for Latin America and the Caribbean. "UNAIDS is working alongside national authorities, United Nations agencies, community organizations and development partners to help ensure support and continued access to HIV treatment, care and information...

UNICEF [to 04 Jul 2026]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements [Selected]
Statement 30 June 2026
Joint statement by the Committee on the Rights of the Child and UNICEF on the plight of migrant children in South Africa
GENEVA/NAIROBI, 30 June 2026 -, The Committee on the Rights of the Child and UNICEF express their deep concern regarding the plight of migrant children in South Africa and the challenges they face while moving across the African continent. As enshrined in the Convention on the Rights of the Child and

Press release 30 June 2026
UNICEF aid shipment lands in Venezuela following devastating earthquakes
CARACAS/COPENHAGEN/NEW YORK, 30 June 2026 –, In response to the devastating earthquakes that struck Venezuela on 24 June, a 47-metric-ton shipment of UNICEF humanitarian supplies has arrived in the country today to support children and families affected. The shipment - mobilized from the European Union stockpile ...

Statement 29 June 2026
Children are adopting AI technologies more than three times faster than adults
NEW YORK/FLORENCE, 30 June 2026 – ", AI is here. It is a growing part of all of our lives. And it is already shaping childhood around the world – for better and for worse. "New evidence is laying bare

the scale and speed of its uptake by children worldwide, while exposing the risks and divides emerging alongside i...

Press release 28 June 2026
UNICEF: 680,000 children estimated to be in need of humanitarian assistance after Venezuela earthquakes
CARACAS/NEW YORK, 27 June 2026 -, UNICEF estimates that 1.8 million people, including 680,000 children, are in need of humanitarian assistance following the earthquakes that struck Venezuela on 24 June. Two earthquakes, of magnitude 7.2 and 7.5, struck within a minute of each other on 24 June, in the most signif...

Unitaid [04 Jul 2026]
https://unitaid.org/
News releases
Executive Board marks 20 years of Unitaid and charts a path for the future of health innovation access
03 July 2026

Vaccine Equity Cooperative [nee Initiative] [04 Jul 2026]
https://vaccineequitycooperative.org/news/
News
No new digest content identified. [Last update Jun 30, 2023]

Vaccine Confidence Project [04 Jul 2026]
http://www.vaccineconfidence.org/
News, Research and Reports
The surprising truth about trust in science
July 2, 2026

Vaccine Education Center – Children's Hospital of Philadelphia [04 Jul 2026]
http://www.chop.edu/centers-programs/vaccine-education-center
News
Vaccine Update Newsletter June/July 2026

Wellcome Trust [04 Jul 2026]
https://wellcome.org/
News. Opinion, Reports
No new digest announcements identified.

The Wistar Institute [to 04 Jul 2026]
https://www.wistar.org/news/press-releases
Press Releases
No new digest announcements identified.

World Bank [to 04 Jul 2026]

http://www.worldbank.org/en/news/all
News [Selected]
REPORT: Building Food Security, Creating Jobs Policy Pathways for the Middle East, North Africa, Afghanistan and Pakistan
A World Bank Group regional flagship report, Building Food Security, Creating Jobs, shows that transforming agrifood systems is one of the greatest opportunities to strengthen food and nutrition security...
Date: June 29, 2026 Type: Publication

WFPHA: World Federation of Public Health Associations [04 Jul 2026]
https://www.wfpha.org/
Blog, Events
No new digest announcements identified.

World Medical Association [WMA] [to 06 Sep 025]
https://www.wma.net/news-press/press-releases/
Press Releases
No new digest announcements identified.

World Organisation for Animal Health [WOAH/OIE] [04 Jul 2026]
https://www.oie.int/
Latest News
News
WOAH launches Wildlife Health Strategy 2026–2030 to strengthen prevention, surveillance systems and rapid response capacities

::::::
::::::

ARM [Alliance for Regenerative Medicine] [04 Jul 2026]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest announcements identified.

BIO [04 Jul 2026]
https://www.bio.org/press-releases
Press Releases
No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [04 Jul 2026]
http://www.dcvmn.org/
News; Upcoming events
No new digest announcements identified.

EFPIA – European Federation of Pharmaceutical Industries and Associations
https://www.efpia.eu/news-events/

News & Events
Turning EU excellence in science into commercial success could add more than €120billion to EU economy in 10 years
02.07.26
EFPIA's latest competitiveness analysis, now expanded to include Japan, shows that the EU and Japan are at a similar crossroads. Both have strong scientific foundations and globally recognised pharmaceutical industries, yet face increasing competition from countries that are making life sciences innovation a strategic economic and industrial priority...

ICBA – International Council of Biotechnology Associations [04 Jul 2026]
https://internationalbiotech.org/
News
No new digest announcements identified.

IFPMA [04 Jul 2026]
https://ifpma.org/
News & Resources
Press release 30 June 2026
WIPO, IFPMA and Interpat join forces to support health innovation through IP management clinics
The World Intellectual Property Organization (WIPO), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Interpat have launched a new partnership that underlines a shared commitment to intellectual property supporting health innovation.
The new collaboration is designed to support startups and small and medium-sized enterprises (SMEs) from the health technology, MedTech and biotechnology sectors in making strategic use of intellectual property (IP) to promote innovation.
The Memorandum of Understanding (MoU), signed at WIPO headquarters on June 29, 2026, provides a framework for collaboration that combines WIPO's expertise in intellectual property management delivered through its Intellectual Property Management Clinics (IPMCs), with IFPMA's global network of pharmaceutical industry associations and Interpat's community of senior intellectual property and patent professionals.
The partnership builds on WIPO's established IP Management Clinic methodology. In the past six years, WIPO has delivered more than 100 IPMC workshops in more than 60 countries, supporting over 3,500 SMEs and startups in strategic use of IP.
The new initiative aims to strengthen the ability of innovative companies to manage and leverage IP assets such as patents, trademarks, trade secrets and regulatory data. It is expected to enhance companies' capacity to attract investment, negotiate partnerships and licensing agreements and make greater use of international systems...

Statement 30 June 2026
Global biopharmaceutical CEOs response to reforms introduced in Germany

International Alliance of Patients' Organizations – IAPO [04 Jul 2026]
https://www.iapo.org.uk/news
Press and media [Selected]
No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/
News
No new digest announcements identified.

PhRMA [04 Jul 2026]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

::::::
::::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements
We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca
Press Releases - *No new digest announcements identified.*

Bavarian Nordic
Latest News
June 29, 2026
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
... The single-dose vaccine is the first virus-like particle (VLP) vaccine approved in Canada for protection against the mosquito-borne chikungunya virus, expanding preventive options for travelers to endemic and outbreak regions...

BioCubaFarma – Cuba
Últimas Noticias - *No new digest announcements identified.*

Biological E
News - *No new digest announcements identified.*

BioNTech
Press Releases - *No new digest announcements identified.*

Boehringer
Press Releases - *No new digest announcements identified.*

CanSinoBIO
News - *Website not responding at inquiry.*

CIGB
Latest News
Speech by the Director General at the Central Ceremony for the 40th Anniversary of the Center for Genetic Engineering and Biotechnology
2 de julio de 2026

CinnaGen – Iran
CinnaGen News - *No new digest announcements identified.*

Clover Biopharmaceuticals – China
News - No new digest announcements identified.

CSL Sequirus
News Releases - No new digest announcements identified.

Curevac
News - Website now directs to BioNTech site

Daiichi Sankyo
Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik
Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]
https://sputnikvaccine.com/ - No new digest announcements identified [Last: 31 Aug 2022]

GSK
Press releases for media - No new digest announcements identified.

EuBiologics, S Korea
News - No new digest announcements identified.

HIPRA
Press releases - No new digest announcements identified.

JNJ Innovative Medicine [Janssen]
Press Releases - No new digest announcements identified.

Merck
News releases - No new digest announcements identified

Moderna
News and Blog Posts - No new digest announcements identified.

Nanogen
News - No new digest announcements identified.

Novartis
News - No new digest announcements identified.

Novavax
Press Releases - No new digest announcements identified.

Pfizer
Recent Press Releases - No new digest announcements identified.

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Samsung Biologics
Latest News

June 30, 2026
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth

Sanofi Pasteur
Press Releases - *No new digest announcements identified*

Serum Institute
News & Announcements - *No new digest announcements identified*

Sinopharm/WIBPBIBP
News - *No new digest announcements identified.*

Sinovac
Press Releases
2026/06/24
SINOVAC Expands Egypt Partnership with Localized Influenza and sIPV Vaccine Production
BEIJING, June 24, 2026 — SINOVAC and GENNVAX, Egyptian local partner, signed an agreement for the localized production of influenza and Sabin-strain inactivated poliovirus (sIPV)

SK Biosciences
Press Releases
SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions
2026.07.02
:: SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework.
:: SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.
:: The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.

Takeda
Newsroom - *No new digest announcements identified.*

Valneva
Press Releases - *No new digest announcements identified.*

WestVac Biopharma
Media - *No new digest announcements identified.*

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
Website *[No News/Announcements page identified]*

::::::
::::::

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: Organization Announcements

:: Journal Watch
:: Pre-Print Servers

::::::
::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 17 2026 Issue 2
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 27, Number 12: E823-875 December 2025
https://journalofethics.ama-assn.org/issue/aging-bad-you
Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics
Jun 04, 2026 Volume 113 Issue 6 p1125-1364
https://www.cell.com/ajhg/current
This month in *The Journal*
Paul W. Hook, Alyson B. Barnes

Existing best practices for pre-clinical and clinical research are not well-suited for individualized therapeutic approaches that leverage new treatment modalities, such as antisense oligonucleotides (ASOs). The increasing number of individualized ASOs in clinical use has driven rapid changes in FDA regulatory frameworks, patient eligibility criteria, and approaches to clinical risk management. In a typical clinical trial setting, detailed consent occurs once, and extensive pre-clinical data provides an estimate of benefits and risks.
[Reviewed earlier]

American Journal of Infection Control
July 2026 Volume 54 Issue 7 p733-828
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
June 2026 Volume 70 Issue 6
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
June 2026 116(6)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 114 (2026): Issue 6 (Jun 2026)
https://www.ajtmh.org/view/journals/tpmd/114/4/tpmd.114.issue-6.xml
[Reviewed earlier]

Annals of Internal Medicine
June 2026 Volume 179, Issue 6
https://www.acpjournals.org/toc/aim/current
Latest 30 June 2026
Original Research
Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone
Yan Xie, PhD, Taeyoung Choi, MS, and Ziyad Al-Aly, MD
Abstract
Background: Safety studies of the COVID-19 vaccine have identified some adverse events. Yet newer variant-updated formulations, along with increased hybrid immunity, may change these risks. Early-era safety data may not reflect experience with updated formulations in more immune-experienced populations.
Objective: To evaluate 90-day risks for adverse events after coadministration of COVID-19 and influenza vaccines compared with influenza vaccination alone, across bivalent, XBB-adapted, and KP-adapted COVID-19 vaccine periods.
Design: Target trial emulation using electronic health care data.
Setting: U.S. Department of Veterans Affairs.
Participants: Participants receiving both COVID-19 and seasonal influenza vaccines (n = 705 124) and those receiving only an influenza vaccine (n = 1 813 205) between 1 September 2022 and 26 August 2025.
Intervention: Receipt of both COVID-19 and seasonal influenza vaccines versus receipt of only an influenza vaccine.
Measurements: 90-day risks for 46 prespecified individual adverse events grouped into 3 composite outcomes (tier 1, serious or life-threatening; tier 2, clinically significant; tier 3, less severe or self-limiting), using weighted discrete-time survival models.

Results: For all 3 composite outcomes, risks were similar between groups: tier 1 (risk ratio [RR], 1.03 [95% CI, 0.99 to 1.09]), tier 2 (RR, 0.99 [CI, 0.96 to 1.03]), and tier 3 (RR, 0.99 [CI, 0.96 to 1.02]). Of the 46 individual adverse events, 2 tier-3 risks had nominal statistical significance: syncope (RR, 1.09 [CI, 1.02 to 1.17]) and tinnitus (RR, 0.95 [CI, 0.92 to 0.99]); no risks were statistically significant after correcting for multiple comparisons. For all risks in tier 1 or tier 2, confidence bounds included 1.0 (no effect). In period-stratified analyses, neither composite (tier) nor individual event estimates supported differences in risks between groups.
Limitation: Generalizability and potential unmeasured confounding.
Conclusion: Same-day coadministration of COVID-19 and influenza vaccines was not associated with an increased risk for adverse events in 3 updated-formulation periods. These findings support the short-term safety of coadministration.
Primary Funding Source: U.S. Department of Veterans Affairs.

Artificial Intelligence – An International Journal
Volume 355 June 2026
https://www.sciencedirect.com/journal/artificial-intelligence/vol/355/suppl/C
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 04 Jul 2026)
Extended cost-effectiveness analysis in global health systems: a scoping review of geographic gaps and research trends
Saman Najafi, Mahmoud Nekoei Moghadam, Reza Goudarzi
Review Open access 28 June 2026

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 04 Jul 2026
Achieving universal health coverage through public health expenditure: an analysis of trends in 187 countries between 2000 and 2021
Aritrik Das, Henna Bhandari, Yukti Bhandari
Research Open access 30 June 2026
Universal health coverage (UHC) is a concept that includes-protection from financial risks for all; access to quality primary health services; and, access to essential medicines and vaccines that are safe, effective, high quality, and inexpensive. Public health expenditure (PHE) is expected to improve healthcare delivery in terms of access, quality and financial risk protection. To this end, this study aims to explore the relationship between progress in UHC and PHE across various countries.

Trends and cross-county disparities in childhood pneumococcal vaccination in Zhejiang Province, China, 2011–2022
Ying Wang, Lingxian Qiu, Shenyu Wang
Research Open access 30 June 2026

Predictors of low trust in national healthcare systems in 30 countries
Andreas Heinz
Research Open access 29 June 2026 Article: 885

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 04 Jul 2026)
Characteristics of *Streptococcus pneumoniae* colonising Cypriot children during a period of high PCV10 and PCV13 vaccine coverage: serotypes and antimicrobial resistance
Gavriella Ioannou Vassiliadou, Petros Ladas, Maria Koliou Mazeri
Research Open access 04 July 2026

Preventive effectiveness of respiratory syncytial virus vaccination in older adults: a multi-institutional cohort study
Chien-Ming Chao, Ya-Wen Tsai, Che-Kim Tan
Research Open access 03 July 2026

Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study
Farah Houdroge, Phillip Luong, Nick Scott
Research Open access 02 July 2026

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 04 Jul 2026)
[No new digest content identified]

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 04 Jul 2026)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 04 Jul 2026)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 04 Jul 2026)
Articles
Behavioral and psychosocial factors associated with coadministration of COVID-19 and influenza vaccines among the elderly
Sujin Seo, Suyoung Jo, Dong-Hyun Kim
Research Open access 03 July 2026

Assessment of hepatitis B and tetanus toxoid vaccination coverage and associated factors among healthcare workers at Kabul University of Medical Sciences affiliated hospitals in Afghanistan
Parvin Golzareh, Shafiqullah Shahim, Mohammad Sedique Yousofzai
Research Open access 03 July 2026

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 04 Jul 2026)
[No new digest content identified]

BMJ Evidence-Based Medicine
June 2026 - Volume 31 - 3
https://ebm.bmj.com/content/31/2
[Reviewed earlier]

BMJ Global Health
June 2026 - Volume 11 - 6
https://gh.bmj.com/content/11/6
Analysis
The impact of the regime change on polio outbreaks in Afghanistan (18 June, 2026)
Mohammad Ismail Zubair, Swetha Ganesan, Kailey Love, William Riley

Commentary
Africa's ownership of a sustainable health journey towards an AIDS-free future (17 June, 2026)
Mumbi Chola, Magda Robalo, Kent Buse, Pokuaa Oduro-Bonsrah, Jekwu Ozoemene, Abdoul Dieng, Ruth Akulu, Bernard Madzima, Awa Marie Coll-Seck, Robb Sheneberger, Sesupo Makakole Nene, Mark Dybul, Izukanji Sikazwe, Michel Sidibe

Complementary role of humanitarian civil society organisations in bridging gaps in immunisation programming in conflict and crisis-affected settings: the REACH Project experience (2 June, 2026)
Comfort Z Olorunsaiye, Lara S Ho, Paul K Malalu, Gautam Chatterjee, Peter Mutanda, Shiferaw Dechasa Demissie, Brooke Amara Farrenkopf, Laura Miller

Original research
Digital payments of health workers within vaccination campaigns: a mixed-methods study in Chad (24 June, 2026)
Esias Ka Nanbe Bedingar, Catherine Wambura, Demilade Osoteku, Antoinette Demian Mbailamen, Adawaye Chatte, Mahamat Fayiz Abakar, Uchenna Igbokwe, Armand Nandoumabe, Briend Donanty Kilone, Muyi Aina, Margaret McConnell

Vaccination coverage and timeliness among children in Ethiopia (19 June, 2026)
Clara Pons-Duran, Bezawit Mesfin Hunegnaw, Chalachew Bekele, Kassahun Alemu, Yayha Mohammed, Kathleen M Kurowski, Fiseha Tadesse, Melkamu Ayalew, Abraham Alebie, Lisanu Taddesse, Delayehu Bekele, Grace J Chan

Strengthening infection prevention and control in humanitarian settings: lessons and opportunities from Médecins Sans Frontières (2021–2023) (5 June, 2026)
Aniroda Broomand, Monique Pereboom, Abdul Mullahzada, Mohana Amirtharajah, Jasper Wagan, Dea Abi Hanna, Lindsay Ross, Mohamad Khalife, Maya Chavez, Chiara Martino, Pilar Garcia-Vello

Bulletin of the Atomic Scientists
DIGITAL MAGAZINE - May 2026

https://thebulletin.org/magazine/2026-05/
[New issue: No digest content identified]

Bulletin of the World Health Organization
Volume 104, Number 6, June 2026, 369-440
https://www.who.int/publications/journals/bulletin
Articles
[Reviewed earlier]

Cell
Jun 11, 2026 Volume 189 Issue 12 p3501-3838
https://www.cell.com/cell/current
Articles
[Reviewed earlier]

Cell and Gene Therapy Insights
February 2026 Issue, Volume 12 Issue 1
https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-1
[Reviewed earlier]

Child Care, Health and Development
Volume 52, Issue 4 July 2026
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 119, Issue 6 Pages: 1393-1673 June 2026
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
June 2026 Volume 48 Issue 6 p485-552
http://www.clinicaltherapeutics.com/current
[New issue: No digest content identified]

Clinical Trials
Volume 23 Issue 3, June 2026
https://journals.sagepub.com/toc/CTJ/current
Articles
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 04 Jul 2026]

[No new digest content identified]

Contemporary Clinical Trials
Volume 166 July 2026
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/166/suppl/C
[Reviewed earlier]

The CRISPR Journal
Volume 9 Issue 3, June 2026
https://journals.sagepub.com/toc/tcja/9/3
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 13, Issue 1 December 2025
https://link.springer.com/journal/40142/volumes-and-issues/13-1
[Reviewed earlier]

Current Medical Research and Opinion
Volume 42, Issue 1, 2026
https://www.tandfonline.com/toc/icmo20/current
[Reviewed earlier]

Current Opinion in Infectious Diseases
August 2026 - Volume 39 - Issue 4
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
https://journals.sagepub.com/toc/tcja/9/3
[New issue; No digest content identified]

Current Protocols in Human Genetics
https://currentprotocols.onlinelibrary.wiley.com/journal/19348258
[Accessed 04 Jul 2026]
[No new digest content identified]

Cytotherapy
June 2026 Volume 28 Issue 6
https://www.isct-cytotherapy.org/current
[Reviewed earlier]

Developing World Bioethics
Volume 26, Issue 2 Pages: 81-130 June 2026
https://onlinelibrary.wiley.com/toc/14718847/current
Special Issue: Military Global Health Engagements
[Reviewed earlier]

Development in Practice
Volume 36, 2026 Issue 4
https://www.tandfonline.com/toc/cdip20/36/4?nav=tocList
[Reviewed earlier]

Development Policy Review
Volume 44, Issue 4 July 2026
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 20 - 2026
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 50, Issue 3 July 2026
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

eBioMedicine
Volume 128 June 2026
https://www.sciencedirect.com/journal/ebiomedicine/vol/128/suppl/C
[New issue: No digest content identified]

EMBO Reports
Volume 27, Issue 9 May 2026
https://link.springer.com/journal/44319/volumes-and-issues/27-9
[Reviewed earlier]

Emerging Infectious Diseases
Volume 32, Number 6—June 2026
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 55 June 2026
https://www.sciencedirect.com/journal/epidemics/vol/55/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 154 - 2026

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 48, Issue 3 Pages: 1-46 May–June 2026
https://onlinelibrary.wiley.com/toc/25782363/current
[Reviewed earlier]

Ethics & International Affairs
Volume 39 - Issue 4 - Winter 2025
https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 33 2025
https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/33/suppl/Cc
[Reviewed earlier]

The European Journal of Public Health
Volume 36, Issue 3, June 2026
https://academic.oup.com/eurpub/issue/36/3
Editorials
Editor's Choice
From prestige to solidarity: why WHO collaborating centres must become a political force
Tiago Correia and Natasha Azzopardi-Muscat

Universal duties in a fragmented world: why Europe must reclaim Kantian ethics for global health governance
Martin McKee and Tiago Correia

Expert Review of Vaccines
Volume 25, 2026 Issue 1
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
May/June 2026 Volume 105, Number 3
https://www.foreignaffairs.com/issues/2026/105/3
[Reviewed earlier]

Forum for Development Studies
Volume 53, 2026 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities
[New issue: No digest content identified]

Frontiers in Genetics
https://www.frontiersin.org/journals/genetics
[Accessed 04 Jul 2026]
Original Research
Accepted on 02 Jul 2026
A workshop considering genetic research and data collection with American Indian and Alaska Native people outside of Tribal jurisdiction
Julie A Beans, et al

Perspective
Published on 30 Jun 2026
Rethinking scale in AI-driven genomic medicine – The role of small biobanks
Laura Grech, Nikolai Paul Pace

Frontiers in Genome Editing
https://www.frontiersin.org/journals/genome-editing
[Accessed 04 Jul 2026]
[No new digest content identified]

Frontiers in Medicine
https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463
[Accessed 04 Jul 2026]
[No new digest content identified]

Gene Therapy – Nature
Volume 33 Issue 3, May 2026
https://www.nature.com/gt/volumes/33/issues/3
[Reviewed earlier]

Genetics in Medicines
Volume 28, Issue 6 June 2026
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/6
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 04 Jul 2026]
[No new digest content identified]

Global Health Action
Volume 19, Issue 1 (2026)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
December 2025 | Volume 13 | Number 2
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc
[Accessed 04 Jul 2026]
[No new digest content identified]

Global Public Health
Volume 21, Issue 1 (2026)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 04 Jul 2026]
[No new digest content identified]

Health and Human Rights
Volume 28, Issue 2, June 2026
https://www.hhrjournal.org/volume-28-issue-1-june-2026/
Special Section: Children's Right to Health
[Reviewed earlier]

Health Economics, Policy and Law
Volume 21 - Issue 2 - April 2026
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 41, Issue 6, June 2026
https://academic.oup.com/heapol/issue/41/6
[New issue: No digest content identified]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 04 Jul 2026]
[No new digest content identified]

Human Gene Therapy
Volume 37 Issue 11-12, June 2026
https://journals.sagepub.com/toc/hgta/37/11-12
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
[Accessed 04 Jul 2026]
[No new digest content identified]

Immunity
Jun 09, 2026 Volume 59 Issue 6 p1473-1776
https://www.cell.com/immunity/current
[New issue; No digest content identified]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 04 Jul 2026]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
Latest articles
[No new digest content identified]

International Health
Volume 18, Issue 4, July 2026
https://academic.oup.com/inthealth/issue/18/4
Review Articles
Editor's Choice
Antimicrobial stewardship interventions currently implemented at primary healthcare settings across low- and lower-middle-income countries (LLMICS)
Abdulhammed O Babatunde and others

International Human Rights Law Review
Volume 15 (2026): Issue 1 (Jun 2026)
https://brill.com/view/journals/hrlr/hrlr-overview.xml
[Reviewed earlier]

The International Journal of Children's Rights
Volume 34 (2026): Issue 2 (Jun 2026)
https://brill.com/view/journals/chil/34/1/chil.34.issue-2.xml
Table of Contents
Editorial
Who "Owns" Children's Rights in a World of Conflict?

Authors: Jonathan Todres and Ton Liefaard
Pages: 239–244
Online Publication Date: 17 Jun 2026
… In this time of conflict, rising authoritarianism, and often-deliberate indifference (at best) to children's suffering, remaining hopeful can be challenging. It is also understandable to question the power and effectiveness of not just children's rights or human rights law, but the rule of law generally. While might does not make right, at times it feels like we are living in an era of little to no accountability for those who use might to perpetrate children's rights violations and ignore the rule of law.

In our view, this era poses difficult but important questions for both children's rights law and for the role of researchers. We have been reflecting on several themes that we believe merit further exploration.

International Journal of Community Medicine and Public Health
Vol. 13 No. 6 (2026): June 2026
https://www.ijcmph.com/index.php/ijcmph/issue/view/137
Articles
[Reviewed earlier]

International Journal of Epidemiology
Volume 55, Issue 2, April 2026
https://academic.oup.com/ije/issue/55/2
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 19, Issue 1 1 April 2026
https://www.emerald.com/ijhrh/issue/19/1
[Reviewed earlier]

JAMA
June 23/30, 2026, Vol 335, No. 24, Pages 2083-2176
https://jamanetwork.com/journals/jama/currentissue
[New issue: No digest content identified]

JAMA Health Forum
June 2026, Vol 7, No. 6
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
June 2026, Vol 180, No. 6, Pages 593-706
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis

June 2026 - Volume 24 - Issue 6
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
June 2026 Volume 78 Issue 6 p835-956
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 85 (2026)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 51, Issue 3 June 2026
https://link.springer.com/journal/10900/volumes-and-issues/51-3
Human Papillomavirus Vaccine Uptake and its Determinants among Parents of Adolescent Girls in Tanga city, Tanzania
Meshack Morice, Mangilo Aboubakar Cedric, Noel Joseph Makinga
Original Paper 07 January 2026 Pages: 378 - 385

Factors Associated with Human Papillomavirus Vaccination Intention Among Young Men in Japan: A Cross-Sectional Study
Hitomi Ando, Junyi Shen, Hiroko Watanabe
Original Paper Open access 07 March 2026 Pages: 462 - 470

Journal of Development Economics
Volume 182 June 2026
https://www.sciencedirect.com/journal/journal-of-development-economics/vol/181/suppl/C
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 21 Issue 3, July 2026
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
June 2026 - Volume 80 - 6
https://jech.bmj.com/content/80/3
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 19, Issue 2 June 2026
https://onlinelibrary.wiley.com/toc/17565391/current

ARTICLE
Cost-Effectiveness of Vaccination Strategies for COVID-19: A Systematic Review
Yi Yang, Junling Weng, Ying Tao, Bingxing Luo, Dai Lian, Fuming Li, Juntao Yan, Yingyao Chen
e70136
First Published: 30 June 2026

Journal of Global Ethics
Volume 22, Issue 1 (2026)
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 37, Number 2, May 2026
https://muse.jhu.edu/issue/56930
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 28, Issue 3 June 2026
https://link.springer.com/journal/10903/volumes-and-issues/28-3
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 24, Issue 1 (2026)
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of International Development
Volume 38, Issue 4 Pages: 605-769 May 2026
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Law, Medicine & Ethics
Volume 54 - Issue 1 - Spring 2026
https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue
[Reviewed earlier]

Journal of Medical Ethics
June 2026 - Volume 52 - 6
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 13, Issue 2 (2026)

https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

The Journal of Pediatrics
Volume 294 July 2026
https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/294/suppl/C
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
Volume 19, 2026 Issue 1
https://www.tandfonline.com/toc/jppp20/19/1?nav=tocList
[Reviewed earlier]

Journal of Public Health Management & Practice
May/June 2026 - Volume 32 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 47, Issue 2 June 2026
https://link.springer.com/journal/41271/volumes-and-issues/47-2
[Reviewed earlier]

Journal of the Royal Society – Interface
Volume 23, Issue 239 1 June 2026
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]]

Journal of Travel Medicine
Volume 33, Issue 5, July 2026
https://academic.oup.com/jtm/issue
Perspectives
Cruise ships as amplifiers of emerging zoonotic threats: implications of the suspected Andes hantavirus cluster aboard MV *Hondius*Get access
Shweta Thaledi and others
Journal of Travel Medicine, Volume 33, Issue 5, July 2026, taag034,
https://doi.org/10.1093/jtm/taag034
Highlight
The suspected hantavirus cluster aboard MV Hondius highlights the vulnerability of cruise ships to emerging zoonotic threats. The event underscores persistent gaps in maritime outbreak preparedness, multinational surveillance and One Health integration as expedition tourism increasingly intersects with ecologically sensitive environments.

Closed cohorts vs open borders: travel medicine lessons from the Ebola and Andes hantavirus outbreaks
Perry J J van Genderen and others

Journal of Travel Medicine, Volume 33, Issue 5, July 2026, taag045,
https://doi.org/10.1093/jtm/taag045

Contrasting WHO responses to BDBV Ebola and the MV *Hondius* Andes virus cluster show that international outbreak risk depends not only on pathogen severity, but also on surveillance visibility, mobility-network traceability and healthcare-system resilience. Modern travel medicine preparedness must, therefore, prioritize containment capacity alongside pathogen-specific risk assessment.

Editor's Choice

Measles mumps rubella (MMR) vaccination status in international paediatric travellers seen for pre-travel consultation in Minnesota, USA

Robyn M Kaiser and others

The Lancet
Jul 04, 2026 Volume 408 Number 10549 p1-92
https://www.thelancet.com/journals/lancet/issue/current

Editorial

The USA at 250: science in the new gilded age

The Lancet

"A republic, if you can keep it." As the USA commemorates 250 years since the signing of The Declaration of Independence, the "if" in Benjamin Franklin's quip resonates more than ever. The present US administration's injuries and usurpations to the nation's scientific institutions continue to escalate. Some of these abuses have been interrupted by the courts, but damaging executive fiats continue, including the Office of Management and Budget's (OMB) proposed new federal funding rule, Regulation for Federal Financial Assistance. Critics have detailed how it will silence independent experts, codify ideological censorship, prioritise politics over data, and erect new barriers to international collaboration that will stifle federal institutions, academia, and industry alike. The Trump administration's zero-sum approach to peace and prosperity is a folly that contrasts with the history of intellectual freedom and international engagement that has characterised US leadership in health and science.

250 years of US history has created a lot of science to celebrate: 329 Nobel laureates in physics, chemistry, and physiology or medicine; 12 Abel Prizes and 15 Fields Medals. American scientists have pioneered the iron lung and PET; heart surgery and organ transplantation. 200 years after inoculation saved the Continental Army from smallpox at Valley Forge, the CDC led the WHO campaign to rid the world of smallpox. Less than 1 year after the first diagnosis of COVID-19, Operation Warp Speed yielded effective vaccines.

The USA has always put America first, but often with contributions from the same populations the Trump administration now denounces as enemies and agitators. Of those 329 US Nobel laureates, 118 (36%) were born outside of the USA. Many emigrated as refugees fleeing violence and persecution. Albert Sabin, inventor of the live-attenuated oral polio vaccine, arrived in the USA at age 15 years after antisemitic pogroms forced his family to leave their native Poland. Jonas Salk's mother, to whom he credited his interest in medicine that led to development of the first inactivated injectable polio vaccine, was able to follow her sister to the USA at age 12 years thanks to family reunification policies that the current administration derides as "chain migration." Katalin Kariko, whose work on mRNA technology is revolutionising modern vaccines, was already a highly skilled professional before an economic crisis in Hungary shuttered her laboratory and sent her abroad to continue her research. Such achievements have greatly strengthened the USA and benefited the world: the US administration needs to realise that the two ideas are not mutually exclusive, but rather intimately entwined.

Brain gain is not limited to extraordinary achievements; 20% of physicians working in the USA were born and educated abroad, and many help to fill critical shortages providing primary care in underserved rural and urban communities. Nearly half (46%) of people with doctoral-level degrees working in US science and engineering fields are foreign-born.

The USA has long recognised the value of returning the favour. The federal government established the Fulbright Scholarship programme to promote education and cultural exchange after World War 2. Scholarships send students and researchers all over the world—both to and from the USA—with the stipulation that they return to their home countries and use their experiences to the benefit of local communities. Nearly 450 000 scholarships later, Fulbright alumni have become leaders in their fields, including Mariano Barbacid who helped to isolate the first human oncogene and Rosalyn Yalow who worked to develop the radioimmunoassay test. In 2025, political interference from the Trump administration drove 11 of the 12 members of the Fulbright Foreign Scholarship Board to resign, and their seats remain vacant.

41% of the science and engineering research published by US authors in 2024 included international collaborators. However, in May of this year, NIH officials began requiring advanced permission for foreign coauthorship, scrubbing international collaborations from progress reports, and demanding that grantees promise to abandon foreign partnerships. The new OMB rule threatens to go even further. The text is open for public comment until July 13, but in its current form will impose restrictions on indirect costs, travel, data sharing, and technical assistance that threaten to stifle international cooperation in science and education. 250 years after independence, the country must once again decide how to define itself, and what it wants to contribute

Comment
How CEPI can enhance global vaccine equity and transparency
Megan Whiteman, Ronald Tundang, Peter Maybarduk, Hisham Abdullah, Suerie Moon

The Lancet Child & Adolescent Health
Jun 2026 Volume 10 Number 6 p393-468
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
May 2026 Volume 8 Number 5
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Jun 2026 Volume 14 Number 6
https://www.thelancet.com/journals/langlo/issue/current
Articles
[Reviewed earlier]

Lancet Infectious Diseases
Jun 2026 Volume 26 Number 6 p549-650, e209-e267
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Jun 2026 Volume 11 Number 6 e349-e416
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Jun 2026 Volume 14 Number 6 p463-566, e33-e40
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 30, Issue 4 April 2026
https://link.springer.com/journal/10 995/volumes-and-issues/30-4
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 46 Issue 4, May 2026
https://journals.sagepub.com/toc/MDM/current
[Reviewed earlier]

Medical Law International
Volume 26 Issue 2, June 2026
https://journals.sagepub.com/toc/MLI/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 104, Issue 2 Pages: 293-580 June 2026
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Molecular Therapy
Jun 03, 2026 Volume 34 Issue 6 p3135-3708
https://www.cell.com/molecular-therapy/current
[Reviewed earlier]

Nature
Volume 655 Issue 8121, 2 July 2026
https://www.nature.com/nature/volumes/653/issues/8121
Editorial 01 Jul 2026
The complex truth about trust in science
Confidence in science has not collapsed, but scientists have urgent problems to address.

World View 01 Jul 2026
Scientists should recognize their own political biases to build public trust
Public trust in science can't be sustained by the support of narrow constituencies at one end of an ideological spectrum.
Mark Henderson

Comment 01 Jul 2026

Six ways to put the public at the heart of science and policy
Trust in elite institutions is on the wane globally. Building public participation into research and government advice can turn the tide.
Chris Tyler, K. L. Akerlof, David Budtz Pedersen

Perspective 01 Jul 2026
Harmonizing standards and resources for the medical genome
This Perspective examines the challenges and opportunities of genomic sequencing across multiple clinical applications, including genetic therapies, and calls for the establishment of new, centralized reference standards to improve consistency and accuracy in the field of precision medicine.
Euan A. Ashley, Ash A. Alizadeh, Jennifer A. Doudna

Nature Biotechnology
Volume 44 Issue 6, June 2026
https://www.nature.com/nbt/volumes/44/issues/6
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 04 Jul 2026)
[Reviewed earlier]

Nature Genetics
Volume 58 Issue 6, June 2026
https://www.nature.com/ng/volumes/58/issues/6
[Reviewed earlier]

Nature Human Behaviour
Volume 10 Issue 6, June 2026
https://www.nature.com/nathumbehav/volumes/10/issues/6
[Reviewed earlier]

Nature Medicine
Volume 32 Issue 6, June 2026
https://www.nature.com/nm/volumes/32/issues/6
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 25 Issue 6, June 2026
https://www.nature.com/nrd/volumes/25/issues/6
[Reviewed earlier]

Nature Reviews Genetics
Volume 27 Issue 6, June 2026
https://www.nature.com/nrg/volumes/27/issues/6

[Reviewed earlier]

Nature Reviews Immunology
Volume 26 Issue 6, June 2026
https://www.nature.com/nri/volumes/26/issues/6
[Reviewed earlier]

New England Journal of Medicine
Volume 395 No. 1 July 2, 2026
https://www.nejm.org/toc/nejm/medical-journal
[New issue; No digest content identified]

NEJM Evidence
Volume 5 No. 6 June 2026
https://evidence.nejm.org/toc/evid/current
NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
[Reviewed earlier]

njp Vaccines
https://www.nature.com/npjvaccines/
[Accessed 04 Jul 2026]
[Reviewed earlier]

Pediatrics
Volume 157, Issue 6 June 2026
https://publications.aap.org/pediatrics/issue/157/6
[Reviewed earlier]

PharmacoEconomics
Volume 44, Issue 6 June 2026
https://link.springer.com/journal/40273/volumes-and-issues/44-6
Articles
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 04 Jul 2026)
The cell cloud: Adopting systems biology concepts in the era of single-cell immunology
Tal Shay, Christophe O. Benoist, Ricardo Grieshaber-Bouyer
Perspective | published 02 Jul 2026 PLOS Biology
https://doi.org/10.1371/journal.pbio.3003853

Towards globally equitable bioinformatics adoption

Paulyna Magaña, Piraveen Gopalasingam, Jennifer R. Fleming, Oleg Kovalevskiy, Augustin Žídek, ThankGod Echezona Ebenezer, Agata Laydon, Roz Onions, Eva Akurut, Syed Muktadir Al Sium, Yalbi Itzel Balderas-Martínez, Sanjana Fatema Chowdhury, Saikat Chowdhury, Sylvia Christie, Govinda Rao Dabburu, Fatoumata Gnine Fofana, Ronald Galiwango, Mahipal Ganji, Daudi Jjingo, Fredrick Elishama Kakembo, Grace Kebirungi, Shahiid Kiyaga, Ayoub Ksouri, Sanjeet Kumar Mahtha, Vinicius Maracaja-Coutinho, Jack Mason, Jose Arturo Molina-Mora, Patricia P. N. Nabisubi, Emmanuel Nji, Houcemeddine Othman, Martina Soledad Paoletta, Nicole M. Scherer, Bhagya Senadheera, Adrián Gustavo Turjanski, David Twesigomwe, Andrew Walakira, Sameer Velankar, Cath Brooksbank
Perspective | published 01 Jul 2026 PLOS Biology
https://doi.org/10.1371/journal.pbio.3003839

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 04 Jul 2026)
[No new digest content identified]

PLoS Global Public Health
https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 04 Jul 2026)
"This is what a war does"- Trust, information ecosystems and childhood vaccination among Ukrainian parents: A qualitative study
Harriet Dwyer, Nadine Beckmann, Jennifer Palmer, Fedir Lapii, Dorota Kleszczewska, Agnieszka Sochon-Latuszek, Hanna Yahorava, Kateryna Gatsenko, Luisa Enria
Research Article | published 02 Jul 2026 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0006742

Operational research in infectious disease outbreak response: An analysis of the World Health Organization's Disease Outbreak News
Melissa Rosenthal, Jeni Stolow, Florian Vogt, Hannah Barnsley, Eleanor Caine, Daniela Garone, Gail Carson, Lauren Sauer, Victor Del Rio Vilas, Lucia Mullen
Research Article | published 02 Jul 2026 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0005802

How can new TB vaccines be effectively introduced in Indonesia? Insights from diverse stakeholders
Nina Dwi Putri, Ahmad Fuady, Nugroho Soeharno, Aqila Sakina Zafira, Margareta Sirena Valeria, Pratama Wicaksana, Poppy Yuniar, Mardiati Nadjib, Azhiim Yudha, Katherine A. Thomas, Rebecca A. Clark, Sri Rezeki Hadinegoro, Richard G. White
Research Article | published 02 Jul 2026 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0005537

PLoS Medicine
https://journals.plos.org/plosmedicine/
(Accessed 04 Jul 2026)
[No new digest content identified]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/
(Accessed 04 Jul 2026)

Disability as a neglected outcome of neglected tropical diseases: A systematic review
Caio Cesar Leiva Bastos Barrionuevo, Jefferson da Silva Valente, Bernardo Maia da Silva, Cássia da Luz Goulart, Alex Maciel, Aldair Darlan Santos-de-Araújo, Camila Miriam Suemi Sato Barros do Amaral, Eduardo Fernandes da Silva Junior, Stephanie Vitória Alves dos Santos, Erika Gomes, Nadia Cubas-Vega, Guilherme Peixoto Tinoco Arêas, Fernando Almeida-Val
Research Article | published 01 Jul 2026 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0014480

PLoS One
http://www.plosone.org/
[Accessed 04 Jul 2026]

Feasibility and acceptability of an electronic immunization registry in urban Bangladesh
Md. Jawadul Haque, A. K. M. Kamruzzaman, Rajendra Bohara, Chiranjit Das, Md. Tarjumanul Haque Sanij, Abul Fazal Md. Shahabuddin Khan, F. A. M. Anjuman Ara Begum, Nazim Uzzaman
Research Article | published 02 Jul 2026 PLOS ONE
https://doi.org/10.1371/journal.pone.0352972

Spatial distribution of uptake of newly introduced vaccines and its associated factors among children aged 12–35 months in Ethiopia: Multi-scale Geographically Weighted Regression Analysis
Habtamu Guaguahu Feleke, Mulat Belay Simegn, Daniel Tarekegn Worede, Werkneh Melkie Tilahun
Research Article | published 02 Jul 2026 PLOS ONE
https://doi.org/10.1371/journal.pone.0345899

Social vulnerability and spatial patterns of COVID-19 mortality: Global implications for respiratory health equity
Gregory D. Kearney, Ogugua Ndili Obi, Veeranna Maddipati, Gregory Levitin, Guangxiao Hu
Research Article | published 01 Jul 2026 PLOS ONE
https://doi.org/10.1371/journal.pone.0352270

Whole-genome sequencing reveals a previously unrecognized measles virus cluster in Burundi
Néhémie Nzoyikorera, David F. Nieuwenhuijse, Leonard Schuele, Cassien Nduwimana, Armstrong Ndihokubwayo, Théogène Ihorimbere, Denis Niyomwungere, Hayley Cassidy, Marjan Boter, Celestin Nibogora, Richard Molenkamp, Alexis Niyomwungere, Dionis Nizigiyimana, Marie Noelle Uwineza, Idrissa Diawara, Saria Otani, Rogier Bodewes, Frank M. Aarestrup, Marion Koopmans, Joseph Nyandwi, Bas B. Oude Munnink
Research Article | published 30 Jun 2026 PLOS ONE
https://doi.org/10.1371/journal.pone.0351691

Epidemiology of invasive pneumococcal disease in Southwest Sweden during the first eleven years after the introduction of general childhood pneumococcal vaccination
Tor Härnqvist, Karin Bergman, Erik Backhaus, Mats Dahl, Helena Kolberg, Caroline Ström Turesson, Malin Olander, Staffan Nilsson, Rune Andersson, Susann Skovbjerg, Johanna Karlsson
Research Article | published 29 Jun 2026 PLOS ONE
https://doi.org/10.1371/journal.pone.0352333

PLoS Pathogens

http://journals.plos.org/plospathoge ns/
[Accessed 04 Jul 2026]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
June 30, 2026 vol. 123 no. 26
https://www.pnas.org/toc/pnas/123/26
[New issue; No digest content identified]

PNAS Nexus
Volume 5, Issue 5, May 2026
https://academic.oup.com/pnasnexus/issue/5/5
[Reviewed earlier]

Prehospital & Disaster Medicine
Volume 41 - Issue 1 - 2026
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 207 June 2026
https://www.sciencedirect.com/journal/preventive-medicine/vol/207/suppl/C
[Reviewed earlier]

Proceedings of the Royal Society B
Volume 293, Issue 2072 June 2026
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 255 June 2026
https://www.sciencedirect.com/journal/public-health/vol/255/suppl/C
[Reviewed earlier]

Public Health Ethics
Volume 18, Issue 2, July 2025
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Genomics
2026, Vol. 29, No. 1
https://karger.com/phg/issue/29/1
[Reviewed earlier]

Public Health Reports
Volume 141 Issue 3, May/June 2026
https://journals.sagepub.com/toc/phrg/141/3
[Reviewed earlier]

Qualitative Health Research
Volume 36 Issue 7, June 2026
https://journals.sagepub.com/toc/QHR/current
[Reviewed earlier]

Research Ethics
Volume 22 Issue 3, July 2026
http://journals.sagepub.com/toc/reab/current
Original Articles
How community members in Uganda perceive controlled human infection studies
Winfred Nazziwa, et al.

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 04 Jul 2026]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Latest Articles
[No new digest content identified]

Risk Analysis
Volume 46, Issue 7 July 2026
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
https://www.dovepress.com/risk-management-and-healthcare-policy-archive56
[Accessed 04 Jul 2026]
[No new digest content identified]

Royal Society Open Science
Volume 13, Issue 6 1 June 2026
https://royalsocietypublishing.org/toc/rsos/current
[Reviewed earlier]

Science
Volume 393| Issue 6806| 2 Jul 2026
https://www.science.org/toc/science/current
Editorial
250 years of promise
BY H. Holden Thorp
02 Jul 2026: 11

American science at 250
BY Alex Wellerstein, Beronda L. Montgomery, ET AL.
2 Jul 2026

Policy Forum
From Edison's Invention Factory to the new architecture of innovation
BY Ashish Arora, Sharon Belenzon
2 Jul 2026

Johns Hopkins University and the American research enterprise
BY Ronald J. Daniels
2 Jul 2026

WWII and the evolution of US federal research funding
BY Daniel P. Gross, Bhaven N. Sampat
2 Jul 2026

Science and Engineering Ethics
Volume 32, Issue 3 June 2026
https://link.springer.com/journal/11948/volumes-and-issues/32-3
[Reviewed earlier]

Science Translational Medicine
Volume 18| Issue 856| 1 Jul 2026
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Scientific Reports
https://www.nature.com/srep/articles?type=article
[Accessed 04 Jul 2026]
[No new digest content identified]

Social Science & Medicine
Volume 398 June 2026
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/398/suppl/C
Research article Open access
Social value of a childhood QALY - Revealed preferences from pharmaceutical funding decisions in Australia 2005–2023
Jing Jing Li, Duncan Mortimer, Anthony Harris, Emily Lancsar, ... Kirsten Howard
Article 119080

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 04 Jul 2026]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 47, Issue 4 August 2026
https://link.springer.com/journal/11017/volumes-and-issues/47-4
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 71 May–June 2026
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/71/suppl/C
[Reviewed earlier]

Tropical Medicine & International Health
Volume 31, Issue 6 Pages: 657-765 June 2026
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 87 11 July 2026
https://www.sciencedirect.com/journal/vaccine/vol/87/suppl/C
[Reviewed earlier]

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 04 Jul 2026]
Article
Post-Pandemic Resurgence of Pertussis in Southeastern Romania, 2024: Vaccination Gaps, Clinical Severity, and Regional Surveillance Performance
Alina Plesea Condratovici, et al.
Vaccines 2026, 14(7), 595;https://doi.org/10.3390/vaccines14070595 (registering DOI)
3 July 2026
Background/Objectives: Following the COVID-19 pandemic, pertussis resurged sharply across Europe, with 209,674 cases reported in the EU/EEA in 2024. This study characterises the epidemiology of the 2024 pertussis resurgence across five counties of so...

Article
Leveraging Large Language Models to Address Common Vaccination Myths and Misconceptions
Florian Reis, et al.
Vaccines 2026, 14(7), 594; https://doi.org/10.3390/vaccines14070594
2 July 2026

Background/Objectives: Large language models (LLMs) are increasingly used by the public to seek health information, yet their accuracy in addressing common vaccine myths remains unclear. Sycophantic LLM behavior, where models align with rather than c...

Review
Influenza Vaccination During Pregnancy: A Narrative Review on Maternal and Neonatal Outcomes Associated with Seasonal Influenza Infection
María Morales-Suárez-Varela, et al.
Vaccines 2026, 14(7), 593;https://doi.org/10.3390/vaccines14070593
2 July 2026
Seasonal influenza remains an important public health concern worldwide, and pregnant women represent a particularly vulnerable population due to physiological and immunological changes associated with gestation. Influenza infection during pregnancy...

Systematic Review
Economic Evaluations of New Vaccine Introduction in Middle-Income Countries in the Middle East and North Africa Region: A Systematic Review
Chrissy Bishop, et al.
Vaccines 2026, 14(7), 591;https://doi.org/10.3390/vaccines14070591 (registering DOI)
1 July 2026
Background/Objectives: Middle-income countries (MICs) in the Middle East and North Africa (MENA) face financial and health system barriers when introducing new vaccines. The Gavi MICs approach has supported the introduction of pneumococcal conjugate...

Article
Implementation of a Large-Scale Ebola Vaccination Campaign in Rwanda
Rosine Ingabire, et al.
Vaccines 2026, 14(7), 588;https://doi.org/10.3390/vaccines14070588
30 June 2026
Background/Objectives: Ebola Virus Disease (EVD) remains a public health threat in sub-Saharan Africa. The 10th Ebola outbreak in the Democratic Republic of the Congo (DRC) in 2018–2020 led the Rwanda Ministry of Health to launch a large-scale...

Article
Immunization Status and Effectiveness Analysis of Hepatitis B Vaccine Among Preterm Infants in Fujian Province, 2022–2023
Hairong Zhang, et al.
Vaccines 2026, 14(7), 583;https://doi.org/10.3390/vaccines14070583
29 June 2026
Objective: This study evaluated hepatitis B vaccine (HepB) uptake, associated influencing factors, and post-vaccination immune responses among preterm infants residing in Fujian Province. The findings can support targeted improvements in hepatitis B...

Value in Health
June 2026 Volume 29 Issue 6 p921-1140
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

World Medical Journal – Official Journal of The World Medical Association
Nr. 4, December 2025, vol. 71

https://www.wma.net/publications/world-medical-journal/
[Reviewed earlier]

World Development
Volume 205 September 2026
https://www.sciencedirect.com/journal/world-development/vol/205/suppl/C
[Reviewed earlier]

::::::
::::::

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

::::::
::::::

Pre-Print Servers

arXiv
https://arxiv.org/
[Accessed 04 Jul 2026]
[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]
No new digest content identified.

New - **bioRxiv**
https://www.biorxiv.org/content/early/recent
[Accessed 04 Jul 2026]
[Filters: Bioengineering, Evolutionary Biology, Genetics, Genomics, Neuroscience, Synthetic Biology]
No new digest content identified.

medRxiv
https://www.medrxiv.org/content/early/recent
[Accessed 04 Jul 2026]
[Filter: All articles]
Website not fully responding at inquiry.
Epidemiology of antimicrobial use in Malawi: a cross-sectional study using World Health Organisation core antimicrobial use indicators in faith-based health facilities
Evans Chimayi Chirambo, Francis Kachidza Chiumia, Dumisani Enricho Nkhoma, Collins Mitambo, Alex Thawani, Taonga Lindiwe Msiska, Sharon Odeo, Judith Asin, Matias John, Waratchaya Chuaikan, Martin Angwe, Patience Khomani, Innocent Chibwe, Simon Matchado, Chikhulupiliro Chimwaza, Pacharo Matchere, Beatrice Chiweza, Elled Mwenyekonde, Elizabeth Kachidza Kampira, Elimase Kamanga, Zione Salima, Clifford George Banda, Happy Makala
medRxiv 2026.07.01.26357065; doi: https://doi.org/10.64898/2026.07.01.26357065

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 04 Jul 2026]
[Filter: All articles]
No new digest content identified.

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
No new digest content identified.

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 04 Jul 2026]
Research Article Open Access
REVISED - Supporting researcher-led public and community engagement: reflections from an internal engagement funding scheme at a global health research programme
[version 2; peer review: 3 approved with reservations, 1 not approved]
Previously titled: "Evaluation of a Seed Award scheme to promote the involvement of global health researchers in public and community engagement: approaches, challenges and lessons learned"
Huong Van Thuy Quy, Jaom Fisher, Mary Chambers
Abstract
Background
Public and community engagement (PCE) in health research is increasingly promoted by research organizations to strengthen their research culture However, barriers that may make researchers hesitate to undertake PCE activities may be heightened in Global South research settings. To address these challenges, we set up an award scheme at the Oxford University Clinical Research Unit (OUCRU) across four research sites in Vietnam, Indonesia, and Nepal to enable researchers to incorporate public engagement activities in their research.
Methods
The Seed Award scheme followed three steps: 1. A call for applications and funding decisions: Researchers were invited to submit grant applications twice per year. Applications were reviewed and funding decisions made by a committee including external reviewers. 2. Supporting and monitoring: Successful awardees were supported to further develop their proposals, strengthen engagement capacity and to plan evaluation. 3. Reporting and evaluation: Awardees were encouraged to conduct evaluation throughout the activities and to submit an end-of-project report. The scheme itself was evaluated using mixed methods.
Results
Between 2016–2022, 41 small grants were awarded. The majority of awards were granted to senior researchers and research assistants. The rest of the awardees included the PhD students, clinical trial coordinators and other departments such as the training department and public engagement personnel. The PCE team supporting the scheme delivered 19 training sessions to help strengthen awardees PCE capacity.
Conclusions
We conclude that the scheme made a profound impact in encouraging researchers to lead and be involved with PCE activities. During this period, more researchers, of all grades, were active in engagement projects. The scheme was improved by adding mentoring and training. In this paper, we

describe the process of development and implementation of this award programme, which aims to support and promote researcher-led public engagement and reflect on the challenges and lessons learned.

* * * *

Think Tanks

Brookings [to 04 Jul 2026]
http://www.brookings.edu/
Research, Events
No new digest content identified.

Center for Global Development [04 Jul 2026]
https://www.cgd ev.org/
All Research
CASE STUDY
Integrating Aid and Statecraft: Australia's DFAT Model and the US Approach to Strategic Assistance
Conor M. Savoy
June 30, 2026
USAID formally ceased independent operations on July 1, 2025, with its remaining foreign assistance functions absorbed into the US Department of State under a "strategic assistance" framework focused on advancing US foreign policy goals. Australia's merger of AusAID into DFAT suggests that successfu...

Chatham House [to 04 Jul 2026]
https://www.chathamhouse.org/
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [04 Jul 2026]
https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [to 04 Jul 2026]
https://www.csis.org/
Reports [Selected]
No new digest content identified.

IS Global [to 04 Jul 2026]
https://www.isglobal.org/en/
Newsroom
No new digest content identified.

McKinsey Global Institute [to 04 Jul 2026]
https://www.mckinsey.com/mgi/overview
Featured Research
No new digest content identified.

ODI [Overseas Development Institute] [to 04 Jul 2026]
https://odi.org/en/publications/
Publications
Comparing tax and benefit microsimulation models: a guide for analysts in low- and middle-income countries
01 July 2026

Oppression, liberation and humanitarianism in Palestine, Myanmar and Sudan
01 July 2026
Research report

Delivering an ecosystem approach to humanitarian action: proposals from the Advisory Panel on the Future of Humanitarian Action
29 June 2026
Toolkit/guideline

Pew Research Center [to 04 Jul 2026]
https://www.pewresearch.org/
Latest Publications
No new digest content identified.

Rand [to 04 Jul 2026]
https://www.rand.org/pubs.html
Published Research [Selected]
Commentary Jul 2, 2026
Teens Are Turning to Chatbots for Mental Health Help. We Need Rules to Keep Them Safe
With social media, product adoption raced ahead while Congress debated causation and passed no meaningful national protections for children. With AI chatbots, we still have a chance to build something sturdier.

Research Jun 29, 2026
The Ecology of AI Risk
Building on the idea of studying AI using ecological and evolutionary perspectives, we propose a novel approach for assessing risk from AI using indicators derived from theoretical ecology models.

Research Jun 29, 2026
Differences in Rural and Urban Home Healthcare Agency Responses to the COVID-19 Pandemic
With COVID-19 impacting urban and rural communities differently, we examined how home healthcare agencies experienced and responded to the pandemic by rurality.

Urban Institute [to 04 Jul 2026]

https://www.urban.org/research
New Research Publications - Selected
No new digest content identified.

World Economic Forum [to 04 Jul 2026]
https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::
::::::

Public Consultations/Calls for Inputs/Calls for Papers

Call for public consultation – WHO's Procedure for prequalification of vaccines
WHO 12 June 2026 **Please submit your comments by 10 July 2026**
Overview
The World Health Organization (WHO), through its Department of Regulation and Prequalification, provides guidance to the United Nations Children's Fund, other interested United Nations agencies, Member States and international/intergovernmental organizations in their procurement decisions to ensure that vaccines provided through the United Nations and international/intergovernmental agencies for use in national immunization services in different countries are safe, effective and suitable for the target populations at the recommended immunization schedules and with appropriate concomitant products.
Since the last revision published in 2013 in TRS 978, the proposed changes reflect the experience gained through interactions with stakeholders, new regulatory collaborations and implementation of the procedure itself.
You are invited to review the roadmap and input any feedback via this feedback form: Global Review Survey

WMA - Declaration of Taipei Revision Launched *[Ongoing]*
...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.
In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.
Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...
In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

* * * *

Contents [click to move among sections]

:: Milestones, Perspectives
:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2026. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *